**Supplementary Data**

**Legends**

**Supplementary Table S1.** - Overview of previously reported associations and the current replication results for SNPs validated against recurrence risk in the overall NMIBC patient group of the NBCS.

**Supplementary Table S2.** - Overview of previously reported associations and the current replication results for SNPs validated against recurrence risk in TUR-only-treated NMIBC patients of the NBCS.

**Supplementary Table S3.** - Overview of previously reported associations and the current replication results for SNPs validated against recurrence risk in BCG-treated NMIBC patients of the NBCS.

**Supplementary Table S4.** - Overview of previously reported associations and the current replication results for SNPs validated against progression risk in the overall NMIBC patient group of the NBCS.

**Supplementary Table S5.** - Overview of previously reported associations and the current replication results for SNPs validated against progression risk in i.v. chemotherapy-treated NMIBC patients of the NBCS.

**Supplementary Table S6.** - Overview of previously reported associations and the current replication results for SNPs validated against overall survival in the MIBC patient group of the NBCS.

**Supplementary Table S7.** - Overview of previously reported SNP associations with outcome in (chemo-)radiotherapy-treated UBC.

**Supplementary Table S8.** - Overview of previously reported SNP associations with outcome in (platinum-based) systemic chemotherapy-treated UBC**.**

**Supplementary Table S9.** - Overview of current replication results for SNPs validated against progression risk in the overall NMIBC patient group of the NBCS using the original and alternative criterion for progression.

**Supplementary Table S1.** Overview of previously reported associations and the current replication results for SNPs validated against recurrence risk in the overall NMIBC patient group of the NBCS

|  |  |
| --- | --- |
| **Original publication** | **Replication in NBCS seriesa** |
| **Reference** | **Gene** | **SNP ID** | **N (n events)b** | **HR (95% CI), p** | **Val.** | **M/I** | **Info (NBCS1/ NBCS2)** | **A1c** | **A2** | **Genotype counts (A1A1/A1A2/A2A2)** | **Additive model** | **Dominant model** | **Recessive model** |
| **Event** | **No event** | **HR (95% CI), p** | **HR (95% CI), p** | **HR (95% CI), p** |
| Andrew AS et al. BJU Int 2014 [1] | *ALDH2* | rs2238151 | 527 (279 R) NMIBC + MIBC | TC vs. TT:1.08 (0.83-1.40), NPCC vs. TT:2.03 (1.41-2.91), NP;Logrank P < 0.001 | N | I | 0.943/ 0.921 | T | C | 261/263/74 | 300/300/87 | 1.01 (0.90-1.14), 0.860 | 1.01 (0.86-1.20), 0.875 | 1.02 (0.79-1.31), 0.896 |
| *IGF1* | rs5742714 [G]: 9.9% | ? (? R)(In total study: 476 NMIBC (? R)) | GC vs. GG:1.61 (1.19-2.17), NPCC vs. GG: NA;Logrank P = 0.002 | N | I | 0.999/ 0.999 | C | G | 499/94/5 | 547/130/9 | 0.84 (0.69-1.02), 0.084 | 0.83 (0.67-1.03), 0.089 | 0.73 (0.30-1.78), 0.493 |
| Zhang K et al. Tumour Biol 2014 [2] | *NAMPT* | rs2505568d | 325 (95 R) NMIBC + MIBC | AT vs. TT:0.30 (0.09-0.97), 0.03AA vs. TT : NA | N | - | - | - | - | - | - | - | - | - |
| Lee EK et al. Cancer 2013 [3] | *RGS1* | rs1323291 | 421 (232 R) | DOM (AC/CC vs. AA):1.60 (1.13-2.28), 0.0084 | IV | I | 0.939/ 0.941 | T | G | 481/111/6 | 545/127/14 | 0.95 (0.78-1.14), 0.553 | 0.98 (0.80-1.21), 0.873 | 0.52 (0.22-1.21), 0.128 |
| *RGS13* | rs3795617 | 421 (232 R) | ADD (AA vs. AG vs. GG):0.79 (0.65-0.96), 0.0187 | IV | M | M | C | T | 136/318/144 | 204/335/147 | **1.13 (1.01-1.27), 0.033** | **1.26 (1.04-1.53), 0.016** | 1.10 (0.91-1.33), 0.308 |
| *RGS2* | rs16829458 | 421 (232 R) | DOM (AG/AA vs. GG):0.63 (0.41-0.95), 0.0268 | IV | M | M | G | A | 500/94/4 | 589/96/1 | 1.07 (0.87-1.32), 0.512 | 1.05 (0.85-1.31), 0.640 | 1.89 (0.71-5.06), 0.204 |
| Ke HL et al. Carcinogenesis 2013 [4] | *DGRC8* | rs720012 | 421 (232 R) | REC (AA vs. AG/GG):2.65 (1.38-5.08), 0.0034 | EV: F | I | 1/ 1 | G | A | 472/120/6 | 524/145/17 | 1.15 (0.96-1.37), 0.122 | 0.89 (0.73-1.08), 0.241 | 0.50 (0.22-1.11), 0.087 |
| *DGRC8* | rs2073778 | 421 (232 R) | REC (TT vs. CT/CC):2.63 (1.37-5.03), 0.0036 | EV: F | I | 1/ 1 | C | T | 472/120/6 | 524/145/17 | 1.15 (0.96-1.37), 0.122 | 0.89 (0.73-1.08), 0.241 | 0.50 (0.22-1.11), 0.087 |
| Yang X et al. Int J Genomics 2013 [5] | *THBS1* | rs2169830 | 236 (78 R) NMIBC + MIBC | AG vs. AA:1.68 (0.97-2.88), 0.062GG vs. AA:2.63 (1.43-4.83), 0.002AG/GG vs. AA:1.95 (1.20-3.19), 0.007GG vs. AG/AA:2.07 (1.23-3.49), 0.006 | N | I | 0.997/ 0.997 | T | C | 305/237/56 | 356/267/63 | 1.02 (0.90-1.15), 0.759 | 1.02 (0.87-1.20), 0.795 | 1.03 (0.79-1.36), 0.807 |
| Wang M et al. Cancer Res 2012 [6] | *MIR146A* | rs2910164 | 199 (74 R) | GC/CC vs GG:0.58 (0.36-0.94), NP;Logrank P = 0.016 | N | I | 0.998/ 0.990 | G | C | 335/224/39 | 397/248/41 | 1.04 (0.91-1.18), 0.577 | 1.05 (0.89-1.24), 0.541 | 1.03 (0.74-1.42), 0.870 |
| Wei H et al. PLoS One 2012 [7] | *NEIL2* | rs4639 | 399 (211 R) | REC (GG vs. AG/AA):1.90 (1.39-2.59), 6x10-5 | N | I | 0.988/ 0.989 | A | G | 186/287/124 | 209/330/148 | 0.98 (0.87-1.10), 0.715 | 0.96 (0.81-1.15), 0.687 | 0.98 (0.80-1.20), 0.854 |
| *NEIL2* | rs804276 | 399 (211 R) | REC (GG vs. AG/AA):1.89 (1.37-2.59), 9x10-5 | N | I | 0.986/ 0.974 | G | A | 199/282/117 | 217/325/144 | 0.96 (0.86-1.08), 0.495 | 0.95 (0.80-1.13), 0.545 | 0.95 (0.77-1.16), 0.607 |
| *NEIL2* | rs804256 | 399 (211 R) | REC (CC vs. CT/TT):1.95 (1.34-2.84),5x10-4 | N | I | 0.975/ 0.978 | T | C | 244/271/83 | 264/323/98 | 0.97 (0.86-1.10), 0.645 | 0.95 (0.80-1.12), 0.537 | 0.99 (0.79-1.26), 0.966 |
| *NEIL2* | rs1874546 | 396 (208 R) | ADD (GG vs. CG vs. CC):1.38 (1.12-1.70),2x10-3 | N | I | 0.986/ 0.988 | C | G | 380/192/26 | 441/214/30 | 1.02 (0.88-1.17), 0.828 | 1.01 (0.86-1.20), 0.887 | 1.06 (0.71-1.57), 0.780 |
| *NEIL2* | rs804267 | 399 (211 R) | REC (CC vs. CT/TT):0.75 (0.46-1.22),3x10-3 | N | M | M | A | G | 288/246/64 | 313/295/78 | 0.95 (0.84-1.07), 0.392 | 0.92 (0.79-1.08), 0.324 | 0.97 (0.75-1.25), 0.793 |
| *TDG* | rs4135054 | 399 (211 R) | DOM (AG/AA vs. GG):1.59 (1.15-2.20),5x10-3 | N | M | M | C | T | 480/112/6 | 532/143/11 | 0.89 (0.74-1.08), 0.240 | 0.90 (0.73-1.10), 0.282 | 0.73 (0.33-1.64), 0.447 |
| Wang M et al. Oncogene 2010 [8] | *XPF* | rs6498486  | 79 (38 R) | AC/CC vs. AA:2.13 (1.04-4.40), NP;Logrank P = 0.025 | N | I | 0.939/ 0.911 | A | C | 277/269/51 | 355/283/48 | 1.10 (0.97-1.25), 0.146 | 1.15 (0.97-1.36), 0.106 | 1.07 (0.79-1.45), 0.655 |
| Horikawa Y et al. Oncol Rep 2008 [9] | *TP53* | rs1042522  | 87 (49 R) Ta/T1 | Pro/Pro vs. Arg/Arg & Arg/Pro:0.36 (0.14-0.93), 0.035 | N | I | 0.943/ 0.951 | C | G | 318/228/52 | 372/271/44 | 1.07 (0.94-1.22), 0.295 | 1.04 (0.89-1.23), 0.605 | 1.27 (0.94-1.70), 0.117 |
| Ahirwar D et al. Cancer Genet Cytogenet 2008 [10] | *IL6* | rs1800795 [C: 25.2%] |  113 (50 R) | GC vs. GG:0.63 (0.27-1.44), 0.27CC vs. GG:0.41 (0.17-0.94), 0.03 | N | I | 0.991/ 0.984 | G | C | 244/259/95 | 245/348/93 | 0.95 (0.84-1.07), 0.396 | 0.86 (0.73-1.02), 0.082 | 1.09 (0.87-1.35), 0.467 |
| Mittal RD et al. Cancer Biol Ther 2008 [11] | *XRCC1*  | rs25487 | 112 (55 R) | GA vs. GG:1.13 (0.53-2.42), 0.74AA vs. GG:5.27 (1.00-27.65), 0.04 | N | I | 0.996/ 0.996 | C | T | 283/235/80 | 287/297/102 | 0.90 (0.81-1.02), 0.090 | 0.86 (0.73-1.01), 0.072 | 0.90 (0.71-1.14), 0.387 |
| Sanyal S et al. Acta Oncol 2007 [12] | *XRCC1* | rs25487 | 22 (? R) TaG2 treated with instillation therapy (BCG/ MMC) | GA/AA vs. GG:0.4 (0.2-1.0), 0.05 | N | I | 0.996/ 0.996 | C | T | 283/235/80 | 287/297/102 | 0.90 (0.81-1.02), 0.090 | 0.86 (0.73-1.01), 0.072 | 0.90 (0.71-1.14), 0.387 |
| Lin J et al. Clin Genet 2006 [13] | *CDH1* | rs16260 | 274 (138 R) | CA/AA vs. CC:0.68 (0.48-0.96), NP;Logrank P = 0.04 | N | I | 0.966/ 0.966 | C | A | 302/245/51 | 322/289/75 | 0.91 (0.80-1.03), 0.119 | 0.91 (0.77-1.07), 0.236 | 0.80 (0.59-1.07), 0.137 |
| Gu J et al. Clin Cancer Res 2005 [14] | *ERCC6* | rs2228526 | 197 (120 R) | AG/GG vs. AA:1.54 (1.02-2.33), NP | N | I | 1/ 1 | T | C | 378/195/25 | 447/210/29 | 1.05 (0.91-1.21), 0.490 | 1.07 (0.91-1.27), 0.394 | 0.99 (0.66-1.47), 0.943 |
| Zhao H et al. Urology 2005 [15] | *GPX1* | rs1050450 | 200 (122 R) (in whites) | Pro/Leu & Leu/Leu vs. Pro/Pro:0.63 (0.42-0.96), NP;Logrank P = 0.036 | N | I | 0.968/ 0.981 | G | A | 297/256/45 | 343/280/63 | 0.96 (0.84-1.08), 0.483 | 0.98 (0.83-1.16), 0.828 | 0.82 (0.60-1.12), 0.222 |
| Kim EJ et al. Urology 2005 [16] | *OGG1* | rs1052133 | 93 (38 R) | Ser/Ser & Ser/Cys vs. Cys/Cys:OR = 6.49 (1.25-33.33), 0.026 | N | I | 0.945/ 0.938 | C | G | 347/221/30 | 392/254/40 | 0.96 (0.83-1.10), 0.532 | 0.97 (0.82-1.14), 0.697 | 0.85 (0.58-1.25), 0.415 |

**Abbreviations:** SNP: single-nucleotide polymorphism; HR: hazard ratio; CI: confidence interval; M: measured (genotyped); I: imputed; NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer; R: recurrence; BCG: bacillus Calmette-Guérin; MMC: mitomycin; Val.: validation; N: no validation; IV: internal validation; EV:F: external validation failed; NBCS: Nijmegen Bladder Cancer Study; OR: odds ratio; NP: not presented; DOM: dominant; REC: recessive; ADD: additive.

**a** N=1284 NMIBC patients (598 recurrence events; five-year Kaplan-Meier recurrence risk: 50.5 %).

**b** Patient numbercorresponds to the number of NMIBC patients included in the original study unless otherwise specified.

**c** A1: major/reference allele; A2: minor/predictive allele (both according to + strand orientation).

**d** This SNP is not measured or imputed in the NBCS.

**Supplementary Table S2.** Overview of previously reported associations and the current replication results for SNPs validated against recurrence risk in TUR-only-treated NMIBC patients of the NBCS

|  |  |
| --- | --- |
| **Original publication** | **Replication in NBCS seriesa** |
| **Reference** | **Gene** | **SNP ID** | **N (n events)** | **HR (95% CI), p** | **Val.** | **M/I** | **Info (NBCS1/ NBCS2)** | **A1b** | **A2** | **Genotype counts (A1A1/A1A2/A2A2)** | **Additive model** | **Dominant model** | **Recessive model** |
| **Event** | **No event** | **HR (95% CI), p** | **HR (95% CI), p** | **HR (95% CI), p** |
| Ke HL et al. Carcinogenesis 2013 [4] | *DDX20* | rs197412 | 136 (91 R) TUR only | ADD (TT vs. CT vs. CC):0.58 (0.40-0.82), 0.002(pooled: 0.62 (0.48-0.81), 0.00077) | IVEV: P | I | 0.999/ 0.998 | T | C | 74/122/47 | 75/111/34 | 1.10 (0.91-1.32), 0.323 | 1.08 (0.82-1.42), 0.592 | 1.20 (0.87-1.65), 0.256 |
| *DROSHA* | rs12186785 | 136 (91 R) TUR only | DOM (CT/CC vs. TT):2.15 (1.25-3.68), 0.005 | IVEV: F | I | 0.582/ 0.505 | T | C | 199/43/1 | 172/45/2 | 0.79 (0.53-1.18), 0.255 | 0.80 (0.52-1.22), 0.304 | 0.22 (0.01-4.59), 0.331 |
| Chen M et al. Cancer Prev Res (Phila) 2010 [17] | *GLI2* | rs11685068 | 141 (92 R) TUR only | DOM (AG/AA vs. GG):2.19 (1.22-3.93), 0.01(pooled: 2.07 (1.33-3.21), 1.3x10-3) | EV: P | I | 0.864/ 0.891 | C | T | 218/25/0 | 197/23/0 | 1.01 (0.64-1.58), 0.972 | 1.01 (0.64-1.59), 0.962 | NA |
| *SHH* | rs1233560 | 141 (92 R) TUR only | ADD (GG vs. AG vs. AA):1.49 (1.07-2.07), 0.02(pooled: 1.39 (1.14-1.70), 1.0x10-3) | EV: P | M | M | A | G | 56/125/62 | 65/114/41 | 1.18 (0.99-1.41), 0.071 | 1.26 (0.93-1.70), 0.130 | 1.23 (0.92-1.64), 0.157 |
| *GLI2* | rs7605011 | 141 (92 R) TUR only | DOM (AG/AA vs. GG):2.03 (1.14-3.62), 0.02 | N | I | 0.776/ 0.810 | G | A | 212/31/0 | 193/27/0 | 1.06 (0.69-1.64), 0.780 | 1.08 (0.70-1.67), 0.739 | NA |
| *GLI3* | rs3801192 | 141 (92 R) TUR only | DOM (AG/AA vs. GG):0.43 (0.21-0.88), 0.02 | N | I | 0.840/ 0.837 | C | T | 206/36/2 | 186/32/2 | 1.07 (0.75-1.53), 0.692 | 1.08 (0.74-1.58), 0.694 | 1.13 (0.21-6.22), 0.886 |
| *GLI3* | rs17172001 | 141 (92 R) TUR only | DOM (AG/AA vs. GG):3.26 (1.48-7.19), 3x10-3 | EV: F | I | 0.841/ 0.819 | G | A | 221/20/2 | 206/14/0 | 1.13 (0.73-1.74), 0.589 | 1.08 (0.67-1.72), 0.761 | 2.94 (0.62-14.0), 0.176 |
| *GLI2* | rs10170242 | 141 (92 R) TUR only | ADD (GG vs. AG vs. AA):1.58 (1.13-2.20), 0.01 | EV: F | M | M | A | G | 125/95/23 | 118/84/18 | 1.07 (0.89-1.30), 0.470 | 1.08 (0.84-1.39), 0.562 | 1.15 (0.75-1.77), 0.526 |
| *SMO* | rs2718107 | 141 (92 R) TUR only | ADD (CC vs. AC vs. AA):0.71 (0.52-0.96), 0.03 | EV: F | M | M | A | C | 57/138/48 | 67/116/37 | 1.16 (0.97-1.40), 0.111 | 1.32 (0.98-1.77), 0.070 | 1.11 (0.81-1.53), 0.508 |
| *GLI2* | rs2310897 | 141 (92 R) TUR only | ADD (AA vs. AG vs. GG):1.44 (1.01-2.06), 0.05 | EV: F | M | M | G | A | 180/56/7 | 148/65/7 | 0.79 (0.62-1.02), 0.070 | 0.75 (0.56-1.00), 0.052 | 0.84 (0.40-1.79), 0.654 |
| *SUFU* | rs11594179 | 141 (92 R) TUR only | DOM (AG/AA vs. GG):1.57 (1.00-2.45), 0.05 | EV: F | M | M | C | T | 150/90/3 | 143/62/15 | 0.95 (0.76-1.18), 0.635 | 1.09 (0.84-1.42), 0.497 | **0.23 (0.07-0.72), 0.012** |
| Gangwar R et al. Mutat Res 2009 [18] | *OGG1* | rs1052133 | 66 (28 R) non-BCG treated | CG vs. CC:0.89 (0.30-2.60), 0.83GG vs. CC:4.04 (1.33-12.1), 0.013 | N | I | 0.945/ 0.938 | C | G | 137/93/13 | 114/91/16 | 0.94 (0.76-1.17), 0.575 | 0.93 (0.71-1.20), 0.569 | 0.93 (0.51-1.69), 0.805 |
| Mittal RD et al. Cancer Biol Ther 2008 [11] | *XRCC1* | rs1799782 | 35 (19 R) non-BCG treated | CT vs. CC:4.57 (1.10-18.97), 0.03TT vs. CC: NA | N | I | 0.993/ 0.988 | G | A | 204/39/0 | 181/38/1 | 0.94 (0.67-1.31), 0.702 | 0.96 (0.68-1.35), 0.795 | NA |
|  Leibovici D et al. J Clin Oncol 2005 [19] | *PPARG* | rs1801282 | 89 (60 R) non-BCG treated | CG/GG vs. CC:0.41 (0.20-0.86), NP | N | I | 0.991/ 0.981 | C | G | 192/47/4 | 172/44/4 | 0.98 (0.74-1.29), 0.893 | 0.98 (0.72-1.34), 0.906 | 0.95 (0.35-2.57), 0.919 |

**Abbreviations:** SNP: single-nucleotide polymorphism; HR: hazard ratio; CI: confidence interval; M: measured (genotyped); I: imputed; NMIBC: non-muscle-invasive bladder cancer; R: recurrence; TUR: transurethral resection; BCG: bacillus Calmette-Guérin; Val.: validation; N: no validation; IV: internal validation; EV: F: external validation failed; EV: P: external validation passed; NBCS: Nijmegen Bladder Cancer Study; NP: not presented; NA: not assessed; DOM: dominant; ADD: additive.

**a** N=463 TUR-only treated patients (243 recurrence events; five-year Kaplan-Meier recurrence risk: 56.5 %).

**b** A1: major/reference allele; A2: minor/predictive allele (both according to + strand orientation).

**Supplementary Table S3.** Overview of previously reported associations and the current replication results for SNPs validated against recurrence risk in BCG-treated NMIBC

patients of the NBCS

|  |  |
| --- | --- |
| **Original publication** | **Replication in NBCS seriesa** |
| **Reference** | **Gene** | **SNP ID** | **N (n events)b** | **HR (95% CI), p** | **Val.** | **M/I** | **Info (NBCS1/ NBCS2)** | **A1c** | **A2** | **Genotype counts (A1A1/A1A2/A2A2)** | **Additive model** | **Dominant model** | **Recessive model** |
| **Event** | **No event** | **HR (95% CI), p** | **HR (95% CI), p** | **HR (95% CI), p** |
| Lima L et al. BJU Int 2014 [20] | *ICAM1* | rs5498 | 204 (70 R) | GG vs. AA/AG:1.76 (1.05-2.95), 0.032 | N | M | M | A | G | 28/37/8 | 39/57/23 | 0.83 (0.59-1.15), 0.256 | 0.89 (0.56-1.43), 0.632 | 0.57 (0.27-1.19), 0.137 |
| *IL2RA* | rs2104286 | 204 (70 R) | CT vs. TT :2.01 (1.21-3.34), 0.007CC vs. TT :1.25 (0.48-3.26), 0.655 | N | I | 0.988/ 0.990 | T | C | 48/21/4 | 68/44/7 | 0.84 (0.56-1.26), 0.401 | 0.78 (0.48-1.28), 0.330 | 0.94 (0.33-2.68), 0.909 |
| *IL17A* | rs2275913 | 204 (70 R) | AA vs. GG/GA:2.10 (1.12-3.93), 0.021 | N | M | M | G | A | 36/29/8 | 56/44/19 | 0.90 (0.65-1.25), 0.539 | 0.94 (0.59-1.49), 0.794 | 0.72 (0.35-1.50), 0.381 |
| *TNF* | rs1799964 | 204 (70 R) | CC vs. TT/TC:2.43 (1.14-5.15), 0.021 | N | I | 0.998/ 0.998 | T | C | 43/24/6 | 78/32/9 | 1.19 (0.84-1.69), 0.333 | 1.28 (0.80-2.03), 0.308 | 1.20 (0.52-2.78), 0.662 |
| *CCR2* | rs391835 | 204 (70 R) | GA/AA vs. GG:0.46 (0.23-0.89), 0.022 | N | I | 0.975/ 0.982 | G | A | 22/34/17 | 31/66/22 | 1.07 (0.76-1.51), 0.696 | 0.89 (0.54-1.48), 0.657 | 1.40 (0.81-2.44), 0.228 |
| *TNFRSF10A* | rs13278062 | 204 (70 R) | TG/GG vs. TT:3.20 (1.37-7.43), 0.007 | N | I | 0.915/ 0.911 | T | G | 20/37/16 | 33/64/22 | 1.09 (0.76-1.55), 0.635 | 1.01 (0.59-1.74), 0.967 | 1.26 (0.70-2.27), 0.433 |
| *IL17RA* | rs4819554 | 204 (70 R) | GG vs. AA/AG:2.89 (1.49-5.63), 0.002 | N | I | 0.985/ 0.991 | A | G | 47/26/0 | 78/36/5 | 0.89 (0.58-1.37), 0.596 | 0.99 (0.61-1.61), 0.983 | NA |
| *FASLG* | rs763110 | 204 (70 R) | CC vs. TT/TC:1.70 (1.02-2.84), 0.042 | N | I | 0.931/ 0.905 | C | T | 27/36/10 | 46/58/15 | 1.06 (0.74-1.52), 0.757 | 1.07 (0.65-1.77), 0.795 | 1.10 (0.53-2.25), 0.803 |
| Andrew AS et al. BJU Int 2014 [1] | *VCAM1* | rs3176879d | ? ( ? R)immuno-therapy(In total study: 479 NMIBC (259 R)) | AG/GG vs. AA:5.0 (1.89-13.17), NP | N | I | 0.388/ 0.406 | - | - | - | - | - | - | - |
| Lima L et al. Urol Oncol 2014 [21] | *FASLG* | rs763110 | 125 (48 R) | CC vs. TC/TT:1.88 (1.04-3.40), 0.037 | N | I | 0.931/ 0.905 | C | T | 27/36/10 | 46/58/15 | 1.06 (0.74-1.52), 0.757 | 1.07 (0.65-1.77), 0.795 | 1.10 (0.53-2.25), 0.803 |
| Jaiswal PK et al. Gene 2013 [22] | *IL18* | rs187238[C]: 28.8% | 78 (34 R) | GC vs. GG:2.35 (1.09-5.10), 0.030CC vs. GG:2.43 (0.50-11.79), 0.269 | N | I | 0.999/ 0.998 | C | G | 35/28/10 | 65/48/6 | 1.38 (0.97-1.96), 0.073 | 1.25 (0.79-1.98), 0.340 | **2.35 (1.20-4.59), 0.013** |
| Srivastava P et al. Urol Oncol 2013 [23] | *MMP2* | rs243865  | 78 (34 R)  | CT vs. CC:4.32 (1.51-12.39), 0.006TT vs. CC:1.36 (0.32-5.76), 0.679CT/TT vs. CC:2.06 (1.01-4.18), 0.047 | N | I | 0.992/ 0.987 | C | T | 38/27/8 | 59/50/10 | 1.07 (0.75-1.53), 0.713 | 0.99 (0.63-1.58), 0.978 | 1.41 (0.67-2.97), 0.361 |
| Wei H et al. PLoS One 2012 [7] | *NEIL2* | rs804256  | 192 (110 R) | REC (CC vs. CT/TT):4.58 (2.61-8.02), 1x10-7 | IV | I | 0.975/ 0.978 | T | C | 33/30/10 | 46/55/18 | 0.88 (0.63-1.23), 0.453 | 0.80 (0.50-1.28), 0.362 | 0.93 (0.47-1.81), 0.828 |
| *NEIL2* | rs804276  | 192 (110 R) | REC (GG vs. AG/AA):2.71 (1.75-4.20), 9x10-6 | IV | I | 0.986/ 0.974 | G | A | 26/35/12 | 40/53/26 | 0.90 (0.65-1.24), 0.505 | 0.94 (0.58-1.53), 0.808 | 0.75 (0.40-1.39), 0.362 |
| *NEIL2* | rs4639 | 192 (110 R) | REC (GG vs. AG/AA):2.60 (1.68-4.03),2x10-5 | IV | I | 0.988/ 0.989 | A | G | 25/33/14 | 38/57/24 | 0.96 (0.69-1.32), 0.786 | 0.92 (0.57-1.49), 0.733 | 0.97 (0.54-1.75), 0.931 |
| *SOD1* | rs2173962 | 192 (110 R) | DOM (AG/GG vs. AA):2.45 (1.42-4.23), 1x10-3 | IV | I | 0.969/ 0.972 | T | C | 70/2/1 | 110/9/0 | 0.72 (0.27-1.91), 0.513 | 0.55 (0.17-1.79), 0.320 | 2.48 (0.34-17.9), 0.367 |
| *NEIL2* | rs804267 | 192 (110 R) | DOM (CT/CC vs. TT):0.53 (0.36-0.78), 1x10-3 | IV | M | M | A | G | 32/30/11 | 57/49/13 | 1.13 (0.81-1.57), 0.472 | 1.12 (0.70-1.77), 0.638 | 1.29 (0.68-2.46), 0.431 |
| *NEIL2* | rs8191604 | 192 (110 R) | DOM (AC/CC vs. AA):0.54 (0.36-0.81), 3x10-3 | IV | I | 0.980 / 0.983 | T | G | 35/30/9 | 66/44/9 | 1.22 (0.86-1.71), 0.263 | 1.24 (0.78-1.98), 0.370 | 1.44 (0.70-2.93), 0.321 |
| Jaiswal PK et al. Mol Biol Rep 2012 [24] | *BIRC5* | rs9904341  | 78 (34 R) | GC vs. GG:0.35 (0.16-0.77), 0.009CC vs. GG:0.22 (0.05-0.95), 0.043 | N | I | 0.994/ 0.995 | G | C | 38/30/5 | 64/50/5 | 1.16 (0.79-1.71), 0.438 | 1.13 (0.71-1.80), 0.596 | 1.52 (0.61-3.76), 0.370 |
| Chiong E et al. Eur Urol 2011 [25] | *GPX1* | rs1050450 | 99 (31 R)BCG +/ IFNα | CT vs. CC:3.0 (1.04-8.6), 0.03TT vs. CC: NA | N | I | 0.968/ 0.981 | G | A | 37/34/2 | 61/49/9 | 0.91 (0.62-1.33), 0.622 | 1.03 (0.65-1.65), 0.896 | 0.36 (0.09-1.51), 0.163 |
| *SLC11A1* | rs17235409 | 69 (23 R)BCG no IFNα | GG vs. GA:3.0 (1.03-8.9), 0.033GG vs. AA: NA | N | I | 0.551/ 0.593 | G | A | 69/4/0 | 110/9/0 | 0.67 (0.20-2.21), 0.506 | 0.67 (0.20-2.22), 0.508 | NA |
| 99 (7 CSD)BCG +/- IFNα | GG vs. GA:44 (1.01-300), 0.036GG vs. AA: NA |  |
| Mittal RD et al. Eur J Surg Oncol 2011 [26] | *CASP3* | rs4647603 | 78 (34 R) | AG vs. AA:1.56 (0.57-4.27), 0.387GG vs. AA:5.20 (1.51-17.96), 0.009AG/GG vs. AA:2.05 (0.82-5.14), 0.124 | N | I | 0.866/ 0.858 | C | T | 52/18/2 | 81/36/2 | 0.94 (0.58-1.53), 0.813 | 0.88 (0.51-1.52), 0.647 | 1.63 (0.38-7.04), 0.516 |
| Gangwar R et al. Surgery 2011 [27] | *PTGS2* | rs20417 | 79 (35 R) | GC/CC vs. GG:2.43 (0.34-1.85), 0.024 | N | I | 0.989/ 0.987 | C | G | 51/20/2 | 75/42/1 | 0.79 (0.49-1.28), 0.341 | 0.73 (0.44-1.21), 0.218 | 1.97 (0.45-8.66), 0.371 |
| Srivastava P et al. Cancer Biomark 2010-2011 [28] | *TP53* | rs1042522  | 78 (34 R) | GC vs. GG:0.29 (0.11-0.84), 0.022CC vs. GG:3.36 (0.62-18.3), 0.161 | N | I | 0.943/ 0.951 | C | G | 40/27/6 | 57/54/9 | 0.85 (0.58-1.23), 0.386 | 0.77 (0.48-1.23), 0.278 | 0.98 (0.42-2.30), 0.959 |
| Chen M et al. Cancer Prev Res (Phila) 2010 [17] | *GLI3* | rs6463089 | 201 (118 R) | DOM (AG/AA vs. GG):2.40 (1.50-3.84), 2x10-4 | IV | M | M | G | A | 61/11/1 | 88/30/1 | 0.66 (0.37-1.19), 0.167 | 0.61 (0.33-1.13), 0.115 | 2.00 (0.28-14.5), 0.492 |
| *GLI3* | rs3801192 | 200 (117 R) | DOM (AG/AA vs. GG):2.54 (1.47-4.39), 9x10-4 | IV | I | 0.840/ 0.837 | C | T | 62/11/1 | 96/22/1 | 0.77 (0.40-1.50), 0.444 | 0.74 (0.37-1.49), 0.394 | 1.35 (0.09-20.8), 0.831 |
| Gangwar R et al. DNA Cell Biol 2010 [29] | *MDM2* | rs2279744  | 79 (36 R) | GT vs. TT:1.35 (0.64-2.85), 0.422GG vs. TT:0.25 (0.08-0.80), 0.019 | N | I | 0.984/ 0.989 | T | G | 32/37/4 | 52/53/14 | 0.85 (0.59-1.22), 0.372 | 0.92 (0.58-1.47), 0.726 | 0.51 (0.18-1.39), 0.186 |
| Gangawar R et al. Med Oncol 2010 [30] | *ERCC2* | rs1799793  | 74 (35 R) | GA vs. GG:0.64 (0.25-1.64), 0.356AA vs. GG:3.07 (1.22-7.68), 0.016 (Pc=0.048) | N | I | 0.927/ 0.904 | C | T | 27/31/15 | 49/62/8 | **1.49 (1.03-2.15), 0.033** | 1.21 (0.73-2.00), 0.462 | **2.76 (1.53-4.99), 7.88x10-4** |
| Gangwar R et al. J Cancer Res Clin Oncol 2010 [31] | *XPC* | rs2228001 | 77 (28 R) | AC vs. AA:1.77 (0.65-4.81), 0.260CC vs. AA:3.21 (1.07-9.61), 0.036AC/CC vs. AA:3.98 (1.02-10.7), 0.031 | N | I | 0.982/ 0.981 | T | G | 29/28/16 | 40/59/20 | 0.96 (0.69-1.34), 0.831 | 0.78 (0.48-1.24), 0.292 | 1.29 (0.74-2.25), 0.366 |
| Ahirwar DK et al. Arch Med Res 2010 [32] | *IL8* | rs4073 | 71 (28 R) | TA vs. TT:0.43 (0.16-1.09), 0.076AA vs. TT:0.12 (0.04-0.38), <0.001 | N | I | 0.989/ 0.984 | T | A | 21/40/12 | 34/61/24 | 0.89 (0.64-1.25), 0.509 | 0.96 (0.58-1.61), 0.886 | 0.73 (0.39-1.37), 0.334 |
| Vázquez-Lavista LG et al. Urology 2009 [33] | *CCL2* | rs1024611 | 33 (16 R/P) | GG vs. AG/AA: associated with BCG response, NP(all non-responders have AA/AG genotype) | N | I | 0.991/ 0.995 | A | G | 37/32/4 | 65/48/7 | 1.03 (0.71-1.51), 0.868 | 1.07 (0.67-1.70), 0.772 | 0.91 (0.33-2.52), 0.853 |
| Gangwar R et al. Mutat Res 2009 [18] | *PRKDC* | rs7003908 | 79 (36 R) | TG vs. TT:0.25 (0.09-0.65), 0.004GG vs. TT:0.44 (0.17-1.11), 0.084 | N | M | M | A | C | 33/37/3 | 50/58/11 | 0.87 (0.60-1.26), 0.446 | 0.95 (0.60-1.50), 0.817 | 0.47 (0.15-1.49), 0.197 |
| Ahirwar DK et al. BJU Int 2009 [34] | *TNF* | rs1799964  | 73 (31 R) | CT vs. TT:1.27 (0.56-2.84), NPCC vs. TT:0.38 (0.14-0.98), 0.024 (Pc=0.048) | N | I | 0.998/ 0.998 | T | C | 43/24/6 | 78/32/9 | 1.19 (0.84-1.69), 0.333 | 1.28 (0.80-2.03), 0.308 | 1.20 (0.52-2.78), 0.662 |
| Gangwar R et al. Ann Surg Oncol 2009 [35] | *CASP9* | rs4645978  | 79 (36 R) | GA vs. AA:0.46 (0.19-1.07), 0.074GG vs. AA:0.22 (0.75-0.62), 0.005 | N | I | 0.985/ 0.988 | T | C | 27/30/16 | 43/56/20 | 1.00 (0.72-1.38), 1.000 | 0.89 (0.55-1.43), 0.617 | 1.19 (0.68-2.09), 0.542 |
| Ahirwar DK et al. Biomarkers 2009 [36] | *TGFB1* | rs1800470 | 73 (30 R) | CT vs. CC:0.68 (0.29-1.56), 0.364TT vs. CC:0.37 (0.14-0.98), 0.046CT/TT vs. CC:0.52 (0.24-1.13), 0.100 | N | I | 0.938/ 0.938 | A | G | 27/34/12 | 44/57/18 | 1.06 (0.75-1.48), 0.751 | 1.04 (0.64-1.70), 0.867 | 1.14 (0.60-2.17), 0.694 |
|  | *IFNG* | rs2430561 | 73 (30 R) | TA vs. TT:2.80 (1.13-6.97), 0.024AA vs. TT:2.09 (0.77-5.66), 0.114TA/AA vs. TT:2.24 (1.06-5.80), 0.036 | N | I | 0.955/ 0.949 | T | A | 18/41/14 | 39/51/29 | 1.03 (0.75-1.42), 0.863 | 1.36 (0.78-2.37), 0.279 | 0.77 (0.42-1.39), 0.383 |
| Ahirwar D et al. Cancer Genet Cytogenet 2008 [10] | *IL6* | rs1800795 | 69 (28 R) | GC vs. GG:0.96 (0.35-2.33), 0.94CC vs. GG:0.30 (0.09-0.91), 0.03 | N | I | 0.991/ 0.984 | G | C | 30/36/7 | 39/58/22 | 0.76 (0.54-1.07), 0.116 | 0.78 (0.49-1.25), 0.305 | 0.53 (0.24-1.15), 0.108 |
| Mittal RD et al Cancer Biol Ther 2008 [11] | *XRCC1* | rs25487 | 57 (25 R) | GA vs. GG:1.63 (0.52-5.16), 0.40AA vs. GG:5.05 (1.34-19.01), 0.01 | N | I | 0.996/ 0.996 | C | T | 35/30/8 | 42/61/16 | 0.74 (0.52-1.06), 0.098 | 0.65 (0.41-1.02), 0.063 | 0.80 (0.38-1.66), 0.544 |
| Decobert M et al. J Urol 2006 [37] | *SLC11A1* | rs17235409 | 67 (51 R) | GA vs. GG:5.74 (2.4-13.8), < 0.0001AA vs. GG: NP | N | I | 0.551/ 0.593 | G | A | 69/4/0 | 110/9/0 | 0.67 (0.20-2.21), 0.506 | 0.67 (0.20-2.22), 0.508 | NA |
| Lin J et al. Clin Genet 2006 [13] | *CDH1* | rs16260 | 48 (18 R)mBCG | CA/AA vs. CC:0.21 (0.07-0.63), NP | N | I | 0.966/ 0.966 | C | A | 33/36/4 | 54/51/14 | 0.90 (0.63-1.29), 0.561 | 1.02 (0.64-1.63), 0.924 | 0.48 (0.17-1.35), 0.164 |
| Basturk B et al. Cytokine 2006 [38] | *TGFB1* | rs1800470 | 60 (14 R/P) | T allele:OR = 7.5 (1.33-55.1), 0.006 | N | I | 0.938 0.938 | A | G | 27/34/12 | 44/57/18 | 1.06 (0.75-1.48), 0.751 | 1.04 (0.64-1.70), 0.867 | 1.14 (0.60-2.17), 0.694 |
| Leibovici D et al. J Clin Oncol 2005 [19] | *IL6* | rs1800795 | 33 (16 R)mBCG | GC vs. GG:4.31 (1.09-17.09), NPCC vs. GG:5.47 (1.05-28.44), NPGC/CC vs. GG:4.60 (1.24-17.09), NP | N | I | 0.991/ 0.984 | G | C | 30/36/7 | 39/58/22 | 0.76 (0.54-1.07), 0.116 | 0.78 (0.49-1.25), 0.305 | 0.53 (0.24-1.15), 0.108 |
| Gu J et al.Clin Cancer Res 2005 [14] | *ERCC6* | rs2228526 | 105 (61 R) | GG vs. AG vs. AA: shorter RFS, Logrank P= 0.022 | N | I | 1/ 1 | T | C | 46/24/3 | 85/30/4 | 1.30 (0.88-1.91), 0.193 | 1.41 (0.87-2.26), 0.159 | 1.20 (0.38-3.83), 0.753 |

**Abbreviations:** SNP: single-nucleotide polymorphism; HR: hazard ratio; CI: confidence interval; M: measured (genotyped); I: imputed; NMIBC: non-muscle-invasive bladder cancer; R: recurrence; P: progression; CSD: cancer-specific death; RFS: recurrence-free survival; (m)BCG: (maintenance) bacillus Calmette-Guérin; IFN: interferon; Val.: validation; N: no validation; IV: internal validation; NBCS: Nijmegen Bladder Cancer Study; OR: odds ratio; NP: not presented; NA: not assessed; REC: recessive; dom: dominant.

**a** N=192 BCG treated NMIBC patients (≥6 instillations) (73 recurrence events; five-year Kaplan-Meier recurrence risk: 41.1 %).

**b** Patient numbercorresponds to the number of BCG treated NMIBC patients included in the original study unless otherwise specified.

**c** A1: major/reference allele; A2: minor/predictive allele (both according to + strand orientation).

**d** This SNP did not pass QC (info < 0.4).

**Supplementary Table S4.** Overview of previously reported associations and the current replication results for SNPs validated against progression risk in the overall NMIBC

patient group of the NBCS

|  |  |
| --- | --- |
| **Original publication** | **Replication in NBCS seriesa** |
| **Reference** | **Gene** | **SNP ID** | **N (n events)b** | **HR (95% CI), p** | **Val.** | **M/I** | **Info (NBCS1/ NBCS2)** | **A1c** | **A2** | **Genotype counts (A1A1/A1A2/A2A2)** | **Additive model** | **Dominant model** | **Recessive model** |
| **Event** | **No event** | **HR (95% CI), p** | **HR (95% CI), p** | **HR (95% CI), p** |
| Lee EK et al. Cancer 2013 [3] | *RGS1* | rs1323291 | 421 (85 P) | DOM (AC/CC vs. AA):2.14 (1.25-3.66), 0.0059 | IV | I | 0.939/ 0.941 | T | G | 159/35/3 | 867/202/18 | 0.96 (0.69-1.33), 0.792 | 0.97 (0.67-1.40), 0.861 | 0.77 (0.21-2.84), 0.698 |
| *RGS5* | rs10917690 | 421 (85 P) | ADD (GG vs. AG vs. AA):0.58 (0.39-0.86), 0.0065 | IV | I | 0.714/ 0.707 | A | G | 108/79/10 | 566/439/81 | 0.83 (0.63-1.10), 0.194 | 0.85 (0.61-1.20), 0.365 | 0.49 (0.20-1.20), 0.119 |
| *RGS4* | rs6678136 | 421 (85 P) | DOM (AG/AA vs. GG):2.07 (1.20-3.57), 0.0094 | IV | M | M | G | A | 55/105/37 | 389/506/192 | 1.18 (0.97-1.43), 0.103 | **1.39 (1.02-1.90), 0.038** | 1.08 (0.75-1.54), 0.677 |
| *RGS5* | rs11585883 | 421 (85 P) | DOM (AG/GG vs. AA):1.93 (1.12-3.32), 0.018 | IV | I | 0.984/ 0.986 | T | C | 166/29/2 | 936/150/1 | 1.20 (0.83-1.75), 0.339 | 1.13 (0.76-1.66), 0.548 | **10.0 (2.47-40.6), 1.27x10-3** |
| Ke HL et al. Carcinogenesis 2013 [4] | *DGCR8* | rs2073778 | 401 (75 P) | REC (TT vs. CT/CC): 4.00 (1.53-10.46), 0.0047 | EV: F | M | M | C | T | 156/37/4 | 840/228/19 | 0.92 (0.68-1.25), 0.595 | 0.88 (0.63-1.24), 0.475 | 1.23 (0.46-3.31), 0.684 |
| *DGCR8* | rs720012 | 399 (75 P) | REC (AA vs. AG/GG):3.97 (1.52-10.36), 0.0049 | EV: F | I | 1/ 1 | G | A | 156/37/4 | 840/228/19 | 0.92 (0.68-1.25), 0.595 | 0.88 (0.63-1.24), 0.475 | 1.23 (0.46-3.31), 0.684 |
| Guirado M et al. Hum Immunol 2012 [39] | *TLR10* | rs4129009 | 275 (66 CSD)NMIBC + MIBC | CT/CC vs. TT:0.49 (0.27-0.90), 0.022 | N | I | 0.936/ 0.921 | T | C | 123/66/8 | 718/332/37 | 1.11 (0.86-1.43), 0.440 | 1.12 (0.83-1.51), 0.461 | 1.18 (0.56-2.52), 0.664 |
| *NOD2* | rs9302752 | 275 (66 CSD)NMIBC + MIBC | GG vs. AA/AG:3.19 (1.40-7.24), 0.006 | N | M | M | C | T | 106/76/15 | 623/411/53 | 1.18 (0.94-1.48), 0.163 | 1.14 (0.86-1.51), 0.351 | 1.56 (0.92-2.64), 0.098 |
| Wei H et al. PLoS One 2012 [7] | *UNG* | rs3890995 | 402 (75 P) | ADD (GG vs. AG vs. AA):1.92 (1.33-2.77), 5x10-4 | IV | I | 0.995/ 0.995 | T | C | 138/51/8 | 731/320/36 | 0.95 (0.73-1.23), 0.691 | 0.90 (0.66-1.22), 0.493 | 1.24 (0.61-2.52), 0.556 |
| Ryk C et al. Scand J Urol Nephrol 2011 [40] | *NOS2* | rs2297518 | 320 (105 P)NMIBC + MIBC | CT vs. CC:1.09 (0.73-1.62), 0.690TT vs. CC:0.21 (0.05-0.87), 0.031 | N | M | M | G | A | 131/63/3 | 700/340/47 | 0.86 (0.66-1.11), 0.248 | 0.90 (0.67-1.22), 0.507 | 0.38 (0.12-1.19), 0.097 |
| Ryk C et al. J Urol 2010 [41] | *NOS2* | rs2301368 | 139 (29 CSD)NMIBC + MIBC | CT vs. CC:3.08 (1.29-7.36), 0.011TT vs. CC:0.34 (0.07-1.63), 0.176 | N | I | 0.923/ 0.926 | A | G | 72/98/27 | 347/543/197 | 1.19 (0.96-1.47), 0.108 | 1.39 (0.91-2.14), 0.132 | 1.20 (0.88-1.63), 0.240 |
| Horikawa Y et al. Oncol Rep 2008 [9] | *TP53* | rs1042522[Pro]/[C]: 41.3% | 86 (26 CSD)Cystectomy treated NMIBC + MIBC | Pro/Pro vs. Arg/Arg & Arg/Pro (CC vs. CG vs. GG):2.76 (1.11-6.84), 0.028 | N | I | 0.943/ 0.951 | C | G | 101/76/20 | 589/423/75 | 1.17 (0.94-1.46), 0.157 | 1.14 (0.85-1.52), 0.390 | 1.54 (0.96-2.48), 0.072 |
| Sanyal S et al. Acta Oncol 2007 [12] | *HRAS* | rs12628 | 196 (? P)Ta/T1(In total study:207 (22 P)) | TC/CC vs. TT:0.3 (0.1-0.9), 0.03 | N | I | 0.907/ 0.910 | A | G | 85/94/17 | 500/454/133 | 0.97 (0.78-1.20), 0.784 | 1.10 (0.81-1.48), 0.540 | 0.66 (0.39-1.13), 0.127 |
| Sanyal S et al. Scand J Urol Nephrol 2007 [42] | *MTHFR* | rs1801133 | 264 (? CSD)NMIBC + MIBC(In total study: 311 (68 CSD)) | CT/TT vs. CC:0.5 (0.3-0.9), 0.03 | N | M | M | G | A | 99/77/21 | 489/475/123 | 0.88 (0.71-1.09), 0.253 | 0.82 (0.62-1.08), 0.160 | 0.95 (0.61-1.50), 0.839 |
| Frey UH et al. Cancer Epidemiol Biomarkers Prev 2005 [43] | *GNAS* | rs7121 | 254 (? P)NMIBC + MIBC | TC vs. TT:1.48 (0.86-2.54), 0.160CC vs. TT:1.94 (1.11-3.38), 0.020 | N | I | 0.758/ 0.715 | C | T | 64/92/41 | 307/539/241 | 0.88 (0.70-1.11), 0.288 | 0.79 (0.56-1.12), 0.190 | 0.91 (0.60-1.38), 0.650 |
| 254 (? MT)NMIBC + MIBC | TC vs. TT:2.71 (1.13-6.48), 0.025CC vs. TT:3.49 (1.46-8.37), 0.005 | N |
| 254 (? CSD)NMIBC + MIBC | TC vs. TT:2.15 (0.95-4.84), 0.065CC vs. TT:2.49 (1.09-5.71), 0.031 | N |
| Eisenhardt A et al. World J Urol 2005 [44] | *GNB3* | rs5443 | 339 (88 MT) NMIBC + MIBC | TT/TC vs. CC:Shorter mean time to metastasis, 0.02 | N | I | 0.963/ 0.962 | C | T | 86/90/21 | 514/465/107 | 1.08 (0.87-1.33), 0.489 | 1.13 (0.84-1.50), 0.420 | 1.04 (0.65-1.67), 0.854 |
| 339 (169 P) NMIBC + MIBC | TT/TC vs. CC:Shorter mean time to progression, 0.042 | N |
| ? (70 CSD)NMIBC + MIBC (non-smokers) | TT/TC vs. CC:1.93 (1.04-3.20), NP;Logrank P = 0.037 | N |
| Sakano S et al. Int J Cancer 2003 [45] | *CDKN2A* | rs3088440 | 211 (23 P)Ta/T1 | CT/TT vs. CC:2.5 (1.0-6.1), 0.043 | N | I | 0.965/ 0.969 | G | A | 159/37/1 | 917/158/12 | 1.21 (0.87-1.68), 0.260 | 1.28 (0.89-1.83), 0.182 | 0.71 (0.12-3.99), 0.694 |

**Abbreviations:** SNP: single-nucleotide polymorphism; HR: hazard ratio; CI: confidence interval; M: measured (genotyped); I: imputed; NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer; P: progression; MT: metastasis; CSD: cancer-specific death; Val.: validation; N: no validation; IV: internal validation; EV:F: external validation failed; NBCS: Nijmegen Bladder Cancer Study; NP: not presented; DOM: dominant; ADD: additive; REC: recessive.

**a** N=1,284 NMIBC patients (197 progression events; five-year Kaplan-Meier progression risk: 17.2 %).

**b** Patient numbercorresponds to the number of NMIBC patients included in the original study unless otherwise specified.

**c** A1: major/reference allele; A2: minor/predictive allele (both according to + strand orientation).

**Supplementary Table S5.** Overview of previously reported associations and the current replication results for SNPs validated against progression risk in i.v. chemotherapy-

treated NMIBC patients of the NBCS.

|  |  |
| --- | --- |
| **Original publication** | **Replication in NBCS seriesa** |
| **Reference** | **Gene** | **SNP ID** | **N (n events)** | **HR (95% CI), p** | **Val.** | **M/I** | **Info (NBCS1/ NBCS2)** | **A1b** | **A2** | **Genotype counts (A1A1/A1A2/A2A2)** | **Additive model** | **Dominant model** | **Recessive model** |
| **Event** | **No event** | **HR (95% CI), p** | **HR (95% CI), p** | **HR (95% CI), p** |
| Sacerdote C et al. Int J Cancer 2013 [46] | *XRCC1* | rs915927 | 114 (? CSD)i.v. /syst. CT treated UBC(In total study: 153 (45 CSD)) | Per allele G:0.55 (0.32-0.94), 0.03 | N | I | 0.975/ 0.974 | T | C | 10/20/9 | 88/116/67 | 1.10 (0.72-1.67), 0.663 | 1.38 (0.67-2.86), 0.380 | 0.93 (0.44-1.96), 0.848 |
| *XRCC1* | rs762507 | 123 (? CSD)i.v. /syst. CT treated UBC | Per allele A:0.48 (0.27-0.84), 0.01 | N | I | 0.975/ 0.974 | C | T | 11/18/10 | 91/114/67 | 1.07 (0.71-1.62), 0.744 | 1.27 (0.63-2.57), 0.502 | 0.94 (0.45-1.98), 0.873 |
| *XRCC1* | rs2854501 | 120 (? CSD)i.v. /syst. CT treated UBC | Per allele T:0.25 (0.12-0.52), 0.001 | EV: F | I | 0.972/ 0.967 | G | A | 24/12/3 | 151/99/22 | 0.84 (0.50-1.40), 0.498 | 0.81 (0.42-1.54), 0.514 | 0.76 (0.21-2.71), 0.673 |
| *XRCC1* | rs2854509 | 122 (? CSD)i.v. /syst. CT treated UBC | Per allele A:0.21 (0.09-0.46), 0.001 | N | I | 0.991/ 0.989 | G | T | 26/11/2 | 156/95/20 | 0.74 (0.43-1.28), 0.285 | 0.69 (0.36-1.35), 0.283 | 0.67 (0.17-2.70), 0.571 |
| *XRCC1* | rs3213255 | 125 (? CSD)i.v. /syst. CT treated UBC | Per allele C:0.46 (0.26-0.80), 0.01 | EV: F | M | M | A | G | 12/18/9 | 88/121/63 | 1.01 (0.66-1.54), 0.965 | 1.06 (0.54-2.10), 0.861 | 0.96 (0.45-2.02), 0.908 |
| *ERCC2* | rs171140 | 121 (? CSD)i.v. /syst. CT treated UBC | Per allele C:2.07 (1.06-4.28), 0.03 | N | I | 0.990/ 0.990 | A | C | 17/16/6 | 87/132/53 | 0.75 (0.47-1.19), 0.221 | 0.63 (0.33-1.19), 0.157 | 0.80 (0.33-1.92), 0.619 |

**Abbreviations:** SNP: single-nucleotide polymorphism; HR: hazard ratio; CI: confidence interval; M: measured (genotyped); I: imputed; NMIBC: non-muscle-invasive bladder cancer; UBC: urinary bladder cancer; i.v.: intravesical; syst.: systemic; CT: chemotherapy; CSD: cancer-specific death; Val.: validation; N: no validation; EV:F: external validation failed; NBCS: Nijmegen Bladder Cancer Study.

**a** N=311 i.v. chemotherapy treated NMIBC patients (39 progression events; five-year Kaplan-Meier progression risk: 14.3 %).

**b** A1: major/reference allele; A2: minor/predictive allele (both according to + strand orientation).

**Supplementary Table S6.** Overview of previously reported associations and the current replication results for SNPs validated against overall survival in the MIBC patient

group of the NBCS

|  |  |
| --- | --- |
| **Original publication** | **Replication in NBCS seriesa** |
| **Reference** | **Gene** | **SNP ID** | **N (n events)b** | **HR (95% CI), p** | **Val.** | **M/I** | **Info (NBCS1/ NBCS2)** | **A1c** | **A2** | **Genotype counts (A1A1/A1A2/A2A2)** | **Additive model** | **Dominant model** | **Recessive model** |
| **Event** | **No event** | **HR (95% CI), p** | **HR (95% CI), p** | **HR (95% CI), p** |
| Andrew AS et al. BJU Int 2014 [1] | *RB1CC1* | rs35402311 | 563 (230 OD)NMIBC + MIBC | CT vs. CC:2.29 (1.54-3.41), NPTT vs. CC: NA;Logrank P = 0.001 | N | I | 0.897/0.874 | G | A | 84/3/0 | 175/13/0 | 0.47 (0.13-1.72), 0.253 | 0.46 (0.12-1.73), 0.252 | NA |
| Djukic TI et al. PLoS One 2013 [47] | *GSTO1* | rs4925 | 101 (62 CSD) | Asp/Asp vs Asp/Ala & Ala/Ala:2.94 (1.16-7.43), 0.022  | N | M | M | C | A | 44/35/8 | 92/81/15 | 0.95 (0.69-1.32), 0.775 | 0.92 (0.60-1.40), 0.692 | 1.02 (0.49-2.10), 0.966 |
| *GSTO2* | rs156697 | 101 (62 CSD) | Asp/Asp vs Asp/Asn & Asn/Asn:3.97 (1.76-8.94), 0.001 | N | M | M | A | G | 38/39/10 | 83/84/21 | 0.98 (0.72-1.34), 0.909 | 0.98 (0.64-1.50), 0.943 | 0.96 (0.50-1.85), 0.897 |
| Lee EK et al. Cancer 2013 [3] | *RGS5* | rs2344673 | 325 (144 OD) | ADD (AA vs. AG vs. GG):1.55 (1.15-2.11), 0.0045 | IV | I | 0.764/ 0.774 | G | A | 69/16/2 | 132/53/3 | 0.67 (0.38-1.17), 0.159 | 0.59 (0.32-1.11), 0.100 | 1.28 (0.21-7.83), 0.789 |
| *RGS5* | rs10917690 | 325 (144 OD) | REC (GG vs. AG/AA):1.88 (1.19-2.96), 0.0066 | IV | I | 0.714/ 0.707 | A | G | 46/39/3 | 105/74/9 | 1.02 (0.65-1.59), 0.932 | 1.12 (0.66-1.90), 0.680 | 0.45 (0.07-2.94), 0.401 |
| *RGS2* | rs1890398 | 325 (144 OD) | DOM (AG/AA vs. GG):1.46 (1.03-2.08), 0.0353 | IV | I | 0.996/ 0.998 | C | T | 37/42/8 | 82/83/23 | 0.98 (0.71-1.34), 0.878 | 1.05 (0.68-1.60), 0.830 | 0.78 (0.38-1.62), 0.513 |
| *RGS3* | rs1051013 | 325 (144 OD) | REC (AA vs. AG/GG): 0.44 (0.20-0.95), 0.0362 | IV | I | 0.995/ 0.995 | C | T | 43/41/3 | 111/60/17 | 1.11 (0.81-1.54), 0.515 | 1.41 (0.93-2.15), 0.106 | 0.43 (0.14-1.37), 0.156 |
| *RGS5* | rs1395960 | 325 (144 OD) | DOM (AG/AA vs. GG):0.53 (0.29-0.96), 0.0377 | IV | I | 0.999/ 0.999 | C | T | 60/25/2 | 143/43/2 | 1.33 (0.88-2.02), 0.173 | 1.32 (0.84-2.08), 0.232 | 2.16 (0.53-8.78), 0.282 |
| *RGS5* | rs12035879 | 325 (144 OD) | REC (AA vs. AG/GG):1.65 (1.02-2.66), 0.0387 | IV | I | 0.619/ 0.607 | G | A | 23/44/20 | 62/101/24 | **1.72 (1.13-2.61), 0.011** | 1.76 (0.88-3.54), 0.110 | **2.79 (1.40-5.56), 3.47x10-3** |
| *RGS12* | rs762861 | 325 (144 OD) | DOM (CG/CC vs. GG):0.69 (0.48-0.98), 0.0389 | IV | I | 0.837/ 0.828 | G | C | 46/36/5 | 94/84/10 | 0.93 (0.63-1.38), 0.723 | 0.90 (0.56-1.43), 0.652 | 1.05 (0.32-3.41), 0.936 |
| *RGS5* | rs10753605 | 325 (144 OD) | REC (GG vs. AG/AA):1.88 (1.03-3.46), 0.0395 | IV | M | M | T | C | 42/42/3 | 88/81/19 | 0.84 (0.60-1.17), 0.294 | 0.94 (0.62-1.44), 0.787 | 0.35 (0.11-1.10), 0.072 |
| Kim EJ et al. Urol Oncol 2012 [48] | *OGG1* | rs1052133 | 113 (42 P) | Ser/Cys vs. Ser/Ser:0.43 (0.21-0.91), 0.027Cys/Cys vs. Ser/Ser:0.28 (0.12-0.70), 0.006 | N | I | 0.945/ 0.938 | C | G | 46/36/5 | 112/66/10 | 1.18 (0.84-1.67), 0.341 | 1.30 (0.84-2.01), 0.236 | 0.98 (0.37-2.58), 0.962 |
| 113 (32 CSD) | Ser/Cys vs. Ser/Ser:0.87 (0.35-2.17), 0.766Cys/Cys vs. Ser/Ser:0.31 (0.10-0.91), 0.033 | N |
| Guirado M et al. Hum Immunol 2012 [39] | *TLR10* | rs4129009 | 275 (66 CSD)NMIBC + MIBC | CT/CC vs. TT:0.49 (0.27-0.90), 0.022 | N | I | 0.936/ 0.921 | T | C | 68/16/3 | 129/52/7 | 0.73 (0.46-1.16), 0.180 | 0.65 (0.38-1.10), 0.109 | 1.04 (0.31-3.47), 0.948 |
| *NOD2* | rs9302752 | 275 (66 CSD)NMIBC + MIBC | GG vs. AA/AG:3.19 (1.40-7.24), 0.006 | N | M | M | C | T | 53/31/3 | 97/78/13 | 0.74 (0.51-1.06), 0.103 | 0.72 (0.47-1.11), 0.140 | 0.54 (0.17-1.69), 0.287 |
| Ha YS et al. Ann Surg Oncol 2011 [49] | *OGG1* | rs1052133 | 117 (41 P) | Ser/Cys vs. Ser/Ser:0.62 (0.30-1.31), 0.214Cys/Cys vs. Ser/Ser:0.31 (0.12-0.84), 0.021 | N | I | 0.945/ 0.938 | C | G | 46/36/5 | 112/66/10 | 1.18 (0.84-1.67), 0.341 | 1.30 (0.84-2.01), 0.236 | 0.98 (0.37-2.58), 0.962 |
| Ryk C et al. Scand J Urol Nephrol 2011 [40] | *NOS2* | rs2297518 | 320 (105 P)NMIBC + MIBC | CT vs. CC :1.09 (0.73-1.62), 0.690TT vs. CC :0.21 (0.05-0.87), 0.031 | N | M | M | G | A | 65/20/2 | 129/55/4 | 0.83 (0.54-1.29), 0.412 | 0.79 (0.49-1.28), 0.333 | 1.15 (0.28-4.69), 0.843 |
| Chen M et al. Carcinogenesis 2010 [50] | *AKT2* | rs3730050  | 302 (125 OD) | wv vs. ww (AG vs. GG):1.51 (1.02-2.23), 0.05vv vs. ww (AA vs. GG):2.99 (1.65-5.42), 2x10-4ADD (AA vs. AG vs. GG):NP, 4x10-4 | IV | M | M | C | T | 35/45/7 | 85/84/19 | 1.01 (0.73-1.39), 0.950 | 1.12 (0.73-1.72), 0.605 | 0.76 (0.35-1.64), 0.481 |
| *PIK3R1* | rs10515074  | 300 (125 OD) | wv vs. ww (AG vs. AA):1.88 (1.27-2.78), 2x10-3vv vs. ww (GG vs. AA):1.37 (0.48-3.94), 0.56DOM (AG/GG vs. AA): 1.83 (1.24-2.69), 2x10-3 | IV | M | M | A | G | 56/28/3 | 116/62/10 | 0.91 (0.63-1.32), 0.618 | 0.92 (0.59-1.43), 0.716 | 0.73 (0.23-2.31), 0.592 |
| *RPTOR* | rs9906827  | 299 (125 OD) | wv vs. ww (AG vs. GG):0.55 (0.36-0.84), 6x10-3vv vs. ww (AA vs. GG):0.54 (0.34-0.88), 0.01DOM (AG/AA vs. GG):0.55 (0.37-0.81), 2x10-3 | IV | I | 0.997/ 0.996 | C | T | 28/30/29 | 59/88/41 | 1.15 (0.87-1.52), 0.339 | 0.96 (0.61-1.50), 0.854 | 1.52 (0.97-2.38), 0.065 |
| *RPTOR* | rs7208502  | 300 (125 OD) | wv vs. ww (AG vs. GG):0.55 (0.36-0.84), 6x10-3vv vs. ww (AA vs. GG):0.54 (0.33-0.87), 0.01DOM (AG/AA vs. GG):0.54 (0.37-0.80), 2x10-3 | IV | M | M | C | T | 28/30/29 | 59/88/41 | 1.15 (0.87-1.53), 0.318 | 0.96 (0.62-1.51), 0.876 | 1.53 (0.98-2.40), 0.060 |
| Ryk C et al. J Urol 2010 [41] | *NOS2* | rs2301368 | 139 (29 CSD)NMIBC + MIBC | CT vs. CC:3.08 (1.29-7.36), 0.011TT vs. CC:0.34 (0.07-1.63), 0.176 | N | I | 0.923/ 0.926 | A | G | 30/38/19 | 53/96/38 | 1.12 (0.82-1.54), 0.476 | 0.92 (0.54-1.56), 0.749 | 1.39 (0.87-2.21), 0.163 |
| Mason RA et al. Carcinogenesis 2009 [51] | *EGFR* | rs2017000 | 577 (? OD)NMIBC + MIBC | GG/AG vs. AA:0.6 (0.3-1.0), NP | N | I | 0.994/ 0.994 | A | G | 56/25/6 | 100/75/13 | 0.80 (0.56-1.15), 0.225 | 0.70 (0.45-1.09), 0.119 | 1.04 (0.45-2.39), 0.922 |
| *EGFR* | rs2227983 | 515 (? OD)NMIBC + MIBC | AA/AG vs. GG:0.3 (0.1-0.9), NP | N | I | 0.994/0.990 | G | A | 60/22/5 | 109/70/9 | 0.78 (0.53-1.14), 0.198 | 0.67 (0.43-1.06), 0.088 | 1.19 (0.48-2.95), 0.701 |
| *EGF* | rs971696 | ? (? OD)NMIBC + MIBC | AT vs. TT:1.5 (1.0-2.3), NP | N | I | 0.939/ 0.911 | A | T | 76/11/0 | 161/25/2 | 0.78 (0.41-1.47), 0.438 | 0.81 (0.41-1.59), 0.538 | NA |
| Castillejo A et al. Int J Cancer 2009 [52] | *TGFBR1* | rs868 | 225 (92 CSD) | AG vs. AA:1.85 (1.15-2.97), NPGG vs. AA:3.00 (1.15-7.82), NP;pLRT = 0.013, ptrend = 0.003 | N | I | 0.983/ 0.971 | A | G | 56/29/2 | 129/55/4 | 1.12 (0.76-1.67), 0.563 | 1.16 (0.74-1.81), 0.518 | 1.00 (0.24-4.08), 0.997 |
| *TGFBR1* | rs334358 | 227 (93 CSD) | GT vs. GG:1.67 (1.05-2.68), NPTT vs. GG:2.83 (1.09-7.34), NP;pLRT = 0.032, ptrend = 0.009 | N | I | 0.982/ 0.970 | G | T | 56/29/2 | 129/55/4 | 1.12 (0.76-1.67), 0.562 | 1.16 (0.74-1.81), 0.516 | 1.00 (0.24-4.08), 0.997 |
| Andrew AS et al. Hum Genet 2009 [53] | *CD80* | rs9282638 | 419 (171 OD)NMIBC + MIBC | Het vs. wt (AG vs. GG):1.9 (1.4-2.8), NPVar vs. wt (AA vs. GG):1.5 (0.2-10.9), NPAny var (AG/AA vs. GG):1.9 (1.4-2.7), NP;Logrank P = 0.008 | N | I | 0.996/ 0.994 | T | C | 65/20/2 | 125/58/5 | 0.79 (0.51-1.22), 0.293 | 0.75 (0.46-1.22), 0.245 | 0.97 (0.24-3.94), 0.961 |
| *BCL2L1* | rs1994251 | 419 (169 OD)NMIBC + MIBC | Het vs. wt (AC vs. AA):1.5 (1.1-2.1), NPVar vs. wt (CC vs. AA):1.5 (0.7-3.3), NPAny var (AC/CC vs. AA):1.5 (1.1-2.1), NP;Logrank P = 0.01 | N | I | 0.999/ 1 | T | G | 51/29/7 | 115/64/9 | 1.09 (0.78-1.53), 0.617 | 1.05 (0.68-1.60), 0.836 | 1.40 (0.65-3.03), 0.395 |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | *EPHX1* | rs2854461 | 419 (172 OD)NMIBC + MIBC | Het vs wt (AC vs. AA):0.8 (0.5-1.1) , NPVar vs. wt (CC vs. AA):0.5 (0.2-0.9) , NPAny var (AC/CC vs. AA):0.7 (0.5-1.0) , NP;Logrank P = 0.02 | N | I | 0.973/ 0.975 | C | A | 31/47/9 | 85/81/22 | 1.16 (0.85-1.58), 0.357 | 1.40 (0.90-2.20), 0.136 | 0.88 (0.44-1.75), 0.710 |
| *ERCC4* | rs1800067 | 419 (172 OD)NMIBC + MIBC | Het vs. wt (AG vs. GG):1.7 (1.1-2.8)Var vs. wt (AA vs. GG):5.6 (1.4-23.4)Any var (AG/AA vs. GG):1.8 (1.2-2.9);Logrank P = 0.1 | N | M | M | G | A | 75/12/0 | 158/29/1 | 0.83 (0.46-1.50), 0.537 | 0.85 (0.46-1.56), 0.595 | NA |
| *GATA3* | rs528778 | 419 (171 OD)NMIBC + MIBC | Het vs. wt (CT vs. CC):0.9 (0.67-1.3) , NPVar vs. wt (TT vs. CC):2.8 (1.6-5.0) , NPAny var (CT/TT vs. CC):1.1 (0.8-1.5) , NP;Logrank P < 0.001 | N | I | 0.933/ 0.944 | C | T | 54/30/3 | 110/70/9 | 0.87 (0.59-1.28), 0.475 | 0.86 (0.55-1.34), 0.501 | 0.77 (0.23-2.61), 0.677 |
| *CXCR2* | rs1126579 | 417 (172 OD)NMIBC + MIBC | Het vs. wt (CT vs. TT):1.7 (1.2-2.5) , NPVar vs. wt (CC vs. TT):1.7 (1.1-2.8) , NPAny var (CT/CC vs. TT):1.7 (1.2-2.5) , NP;Logrank P = 0.003 | N | I | 0.998/ 0.997 | C | T | 22/49/16 | 45/95/48 | 0.86 (0.63-1.17), 0.342 | 0.92 (0.57-1.49), 0.736 | 0.72 (0.41-1.24), 0.230 |
| *UGT1A1* | rs1042640 | 415 (168 OD)NMIBC + MIBC | Het vs. wt (CG vs. GG):1.4 (1.0-2.0) , NPVar vs. wt (CC vs. GG):1.4 (0.6-3.1) , NPAny var (CG/CC vs. GG):1.4 (1.0-2.0) , NP;Logrank P = 0.1 | N | I | 0.976/ 0.962 | C | G | 52/33/2 | 123/58/7 | 1.11 (0.76-1.60), 0.589 | 1.21 (0.78-1.87), 0.397 | 0.69 (0.18-2.63), 0.589 |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | *PGR* | rs613120 | 418 (172 OD)NMIBC + MIBC | Het vs. wt (CT vs. TT):1.2 (0.8-1.9) , NPVar vs. wt (CC vs. TT):1.4 (0.9-2.3) , NPAny var (CT/CC vs. TT):1.3 (0.8-2.0) , NP;Logrank P = 0.005 | N | I | 0.994/ 0.995 | A | G | 19/44/24 | 60/90/38 | 1.33 (1.00-1.79), 0.053 | 1.62 (0.97-2.70), 0.066 | 1.37 (0.85-2.19), 0.194 |
| *AURKA* | rs6024840 | 314 (146 OD)NMIBC + MIBC | Het vs. wt (CT vs. TT):1.4 (1.0-2.1) , NPVar vs. wt (CC vs. TT):1.1 (0.5-2.5) , NPAny var (CT/CC vs. TT):1.4 (1.0-2.0) , NP;Logrank P = 0.1 | N | I | 0.888/ 0.874 | A | G | 46/35/6 | 105/72/11 | 1.08 (0.75-1.55), 0.680 | 1.09 (0.69-1.71), 0.712 | 1.15 (0.45-2.94), 0.764 |
| *TERT* | rs2075786 | 410 (172 OD)NMIBC + MIBC | Het vs. wt (CT vs. TT):0.8 (0.6-1.1) , NPVar vs. wt (CC vs. TT):0.5 (0.3-1.0) , NPAny var (CT/CC vs. TT):0.8 (0.5-1.0) , NP;Logrank P = 0.1 | N | I | 0.719/0.721 | G | A | 34/36/17 | 81/86/21 | 1.27 (0.90-1.80), 0.171 | 1.18 (0.71-1.97), 0.527 | **1.93 (1.01-3.68), 0.045** |
| *CASP9* | rs1052576 | 410 (167 OD)NMIBC + MIBC | Het vs. wt (AG vs. AA):1.3 (0.9-2.0) , NPVar vs. wt (GG vs. AA):1.4 (0.8-2.4) , NPAny var (AG/GG vs. AA):1.3 (0.9-2.0) , NP;Logrank P = 0.003 | N | I | 1/1 | C | T | 25/44/18 | 64/87/37 | 1.10 (0.82-1.48), 0.516 | 1.21 (0.76-1.92), 0.429 | 1.06 (0.63-1.78), 0.819 |
| Horikawa Y et al. Oncol Rep 2008 [9] | *TP53* | rs1042522 | 86 (26 CSD)Cystectomy treated NMIBC + MIBC | Pro/Pro vs. Arg/Arg & Arg/Pro (CC vs. CG vs. GG):2.76 (1.11-6.84), 0.028 | N | I | 0.943/ 0.951 | C | G | 53/31/3 | 102/78/9 | 0.81 (0.55-1.19), 0.285 | 0.78 (0.50-1.22), 0.283 | 0.76 (0.21-2.67), 0.664 |
| Sanyal S et al. Acta Oncol 2007 [12] | *ERCC2* | rs13181 | 260 (? OD)NMIBC + MIBC(In total study: 272 (96 OD)) | AC/CC vs. AA:0.6 (0.4-0.9), 0.008 | N | M | M | T | G | 42/33/12 | 86/73/29 | 0.93 (0.69-1.26), 0.655 | 0.92 (0.60-1.40), 0.689 | 0.90 (0.49-1.66), 0.735 |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sanyal S et al. Scand J Urol Nephrol 2007 [42] | *NQO1* | rs1131341 | 257 (? OD)NMIBC + MIBC (In total study: 311 (113 OD)) | CT/TT vs. CC:1.8 (1.0-3.3), 0.05 | N | I | 0.883/ 0.900 | G | A | 79/8/0 | 180/8/0 | 1.96 (0.91-4.20), 0.083 | 1.96 (0.91-4.20), 0.083 | NA |
| *MTHFR* | rs1801133 | 264 (? CSD)NMIBC + MIBC(In total study: 311 (68 CSD)) | CT/TT vs. CC:0.5 (0.3-0.9), 0.03 | N | M | M | G | A | 42/36/9 | 86/82/20 | 0.93 (0.67-1.28), 0.658 | 0.89 (0.58-1.36), 0.588 | 0.97 (0.49-1.94), 0.940 |
|  Leibovici D et al. J Clin Oncol 2005 [19] | *IL6* | rs1800795 | 149 (? OD)(In total study: 232 (68 OD)) | GC/CC vs. GG (wildtype):0.43 (0.19-0.94), NP | N | I | 0.991/ 0.984 | G | C | 37/39/11 | 68/93/27 | 0.86 (0.62-1.18), 0.339 | 0.79 (0.51-1.21), 0.279 | 0.89 (0.47-1.68), 0.720 |
| 149 (? CSD)(In total study: 232 (38 CSD)) | GC/CC vs. GG (wildtype):0.39 (0.15-1.00), NP | N |
| *TNF* | rs1800629 | 156 (? OD)(In total study: 232 (68 OD)) | GA/AA vs. GG (wildtype):2.35 (1.07-5.16), NP | N | I | 0.997/ 0.999 | G | A | 58/25/4 | 128/53/7 | 1.07 (0.74-1.56), 0.711 | 1.06 (0.68-1.66), 0.801 | 1.26 (0.46-3.45), 0.647 |
| Frey UH et al. Cancer Epidemiol Biomarkers Prev 2005 [43] | *GNAS* | rs7121 | 254 (? P)NMIBC + MIBC | TC vs. TT:1.48 (0.86-2.54), 0.160CC vs. TT:1.94 (1.11-3.38), 0.020 | N | I | 0.758/ 0.715 | C | T | 22/45/21 | 53/89/46 | 1.03 (0.73-1.45), 0.872 | 1.19 (0.65-2.19), 0.573 | 0.92 (0.50-1.67), 0.773 |
| 254 (? MT)NMIBC + MIBC | TC vs. TT:2.71 (1.13-6.48), 0.025CC vs. TT:3.49 (1.46-8.37), 0.005 | N |
| 254 (? CSD)NMIBC + MIBC | TC vs. TT:2.15 (0.95-4.84), 0.065CC vs. TT:2.49 (1.09-5.71), 0.031 | N |
| Eisenhardt A et al. World J Urol 2005 [44] | *GNB3* | rs5443 | 339 (88 MT) NMIBC + MIBC | TT/TC vs. CC:Shorter mean time to metastasis, 0.02 | N | I | 0.963/ 0.962 | C | T | 44/35/8 | 85/83/20 | 0.87 (0.62-1.21), 0.406 | 0.85 (0.55-1.30), 0.443 | 0.80 (0.37-1.73), 0.575 |
| 339 (169 P) NMIBC + MIBC | TT/TC vs. CC:Shorter mean time to progression, 0.042 | N |
| ? (70 CSD)NMIBC + MIBC (non-smokers) | TT/TC vs. CC:1.93 (1.04-3.20), NP;Logrank P = 0.037 | N |

**Abbreviations:** SNP: single-nucleotide polymorphism; HR: hazard ratio; CI: confidence interval; M: measured (genotyped); I: imputed; NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer; OD: overall death; CSD: cancer-specific death; P: progression; MT: metastasis; Val.: validation; N: no validation; IV: internal validation; NBCS: Nijmegen Bladder Cancer Study; LRT: likelihood ratio test; NP: not presented; NA: not assessed; ADD: additive; DOM: dominant; REC: recessive; var (vv): homozygous variant; wt (ww): homozygous wildtype; het (wv): heterozygous variant.

**a** N=275 MIBC patients (87 deceased cases; five-year Kaplan-Meier overall mortality risk: 32.4 %).

**b** Patient numbercorresponds to the number of MIBC patients included in the original study unless otherwise specified.

**c** A1: major/reference allele; A2: minor/predictive allele (both according to + strand orientation).

**Supplementary Table S7.** Overview of previously reported SNP associations with outcome in (chemo-)radiotherapy-treated UBC

|  |
| --- |
| **Original publication** |
| **Reference** | **Gene** | **SNP ID** | **N (n events)** | **HR (95% CI), p** | **Val.** |
|
| Teo MTW et al. Ann Oncol 2014 [54] | *MRE11A* | rs1805363 | 186 (70 CSD)RT-treated MIBC | AG vs. GG:1.49 (0.80-2.78), NPAA vs. GG:8.00 (2.93-21.90), NPPer allele A:2.10 (1.34-3.28), 0.001 | N |
| Teo MT et al. Carcinogenesis 2012 [55] | *RAD51* | rs7180135 | 189 (? CSD)RT-treated MIBC | AG/GG vs. AA:0.52 (0.31-0.87), 0.01 | N |
| Shinohara A et al. Cancer Sci 2009 [56] | *MDM2* | rs2279744 | 95 (19 CSD)Platinum-based CRT treated T1G3/MIBC | TG/GG vs. TT:0.57 (0.36-0.95), 0.031 | N |
| Sanyal S et al. Acta Oncol 2007 [12] | *XRCC1* | rs25487 | 11 (? CSD)RT treated MIBC | GA/AA vs. GG:0.1 (0.0-0.8), 0.03 | N |
| *OGG1* | rs1052133 | 10 (? CSD)RT treated MIBC | CG/GG vs. CC:10.8 (1.2-99.5), 0.04 | N |
| Sanyal S et al. Scand J Urol Nephrol 2007 [42] | *NQO1* | rs1800566 | 11 (? CSD)RT treated MIBC | Variant allele carriers vs. non-carriers:24.4 (1.5-409.0), 0.03 | N |
| Sakano S et al. Br J Cancer 2006 [57] | *XRCC1* | rs25487 | 35 (? CSD)CRT treated T3/T4 patients | GA/AA vs. GG:RR = 0.0004 (NA), 0.02All CRT treated patients:RR= 0.51 (0.20-0.98), 0.04 | N |

**Abbreviations:** SNP: single-nucleotide polymorphism; HR: hazard ratio; CI: confidence interval; MIBC: muscle-invasive bladder cancer; UBC: urinary bladder cancer; RT: radiotherapy; CRT: chemoradiotherapy; CSD: cancer-specific death; Val.: validation; N: no validation; RR: risk ratio; NP: not presented; NA: not assessed.

**Note:** These SNPs were not included in our replication study because of too low patient numbers in the specific MIBC treatment subgroup (*i.e.*, n=36 MIBC patients that received initial treatment with radiotherapy).

**Supplementary Table S8.** Overview of previously reported SNP associations with outcome in (platinum-based) systemic chemotherapy-treated UBC

|  |
| --- |
| **Original publication** |
| **Reference** | **Gene** | **SNP ID** | **N (n events)** | **HR (95% CI), p** | **Val.** |
|
| Gallagher DJ et al. Ann Oncol 2013 [58] | *IL1B* | rs1143627 | 210 (98 response)Platinum-based CT treated, advanced UC | CT vs. TT:OR = 1.81 (0.96-3.44), NPCC vs. TT:OR = 3.38 (1.46-8.18), NP;P = 0.01Per allele C:OR = 1.83 (1.23-2.77), 0.003 | N |
| *IL1B* | rs16944 | 209 (98 response)Platinum-based CT treated, advanced UC | AG vs. GG:OR = 1.89 (1.0-3.62), NPAA vs. GG:OR = 3.56 (1.53-8.69), NP;P = 0.008Per allele A:OR = 1.89 (1.26-2.87),0.002 | N |
| *-* | rs1520896 | 210 (98 response)Platinum-based CT treated, advanced UC | CT vs. CC:OR = 0.75 (0.39-1.42), NPTT vs. CC:OR = 0.18 (0.04-0.61), NP;P = 0.02Per allele T:OR = 0.55 (0.34-0.88), 0.01 | N |
| *CCND1* | rs9344 | 207 (98 response)Platinum-based CT treated, advanced UC | GA vs. GG:OR = 1.71 (0.86-3.46), NPAA vs. GG:OR = 0.38 (0.16-0.89), NP;P = 0.0005Per allele A:OR = 0.67 (0.44-1.0), 0.05 | N |
| *PARD6B* | rs6512670 | 208 (98 response)Platinum-based CT treated, advanced UC | CT vs. CC:OR = 1.22 (0.64-2.34), NPTT vs. CC:OR = 2.82 (1.21-6.84), NP;P = 0.05Per allele T:OR = 1.6 (1.06-2.43), 0.03 | N |
| Sacerdote C et al. Int J Cancer 2013 [46] | *XRCC1* | rs915927 | 114 (? CSD)i.v. /syst. CT treated UBC(In total study: 153 (45 CSD)) | Per allele G:0.55 (0.32-0.94), 0.03 | N |
| *XRCC1* | rs762507 | 123 (? CSD)i.v. /syst. CT treated UBC | Per allele A:0.48 (0.27-0.84), 0.01 | N |
| *XRCC1* | rs2854501 | 120 (? CSD)i.v. /syst. CT treated UBC | Per allele T:0.25 (0.12-0.52), 0.001 | EV: F |
| *XRCC1* | rs2854509 | 122 (? CSD)i.v. /syst. CT treated UBC | Per allele A:0.21 (0.09-0.46), 0.001 | N |
| *XRCC1* | rs3213255 | 125 (? CSD)i.v. /syst. CT treated UBC | Per allele C:0.46 (0.26-0.80), 0.01 | EV: F |
| *ERCC2* | rs171140 | 121 (? CSD)i.v. /syst. CT treated UBC | Per allele C:2.07 (1.06-4.28), 0.03 | N |
| Djukic TI et al. PLoS One 2013 [47] | *GSTO2* | rs156697 | 51 (? CSD)Neo-adjuvant platinum-based CT treated MIBC | Asp/Asp vs Asp/Asn & Asn/Asn:Shorter survival (19.4±3.4 months vs. 40.3±3.7 months)Logrank P = 0.006 | N |
| Nikitas N et al. Pharmacogenomics 2012 [59] | *ERCC1* | rs11615 | 109 (65 CSD)Platinum-based CT treated, advanced UC | TT vs. CC/CT:Multivariable model 1:0.49 (0.25-0.96), 0.037Multivariable model 2:0.42 (0.24-0.87), 0.026 | N |

**Abbreviations:** SNP: single-nucleotide polymorphism; HR: hazard ratio; CI: confidence interval; MIBC: muscle-invasive bladder cancer; UT: urothelial carcinoma; UBC: urinary bladder cancer; CT: chemotherapy; i.v.: intravesical; syst.: systemic; CSD: cancer-specific death; Val.: validation; N: no validation; IV: internal validation; EV:F: external validation failed; OR: odds ratio; NP: not presented.

**Note:** These SNPs were not included in our replication study because of too low patient numbers in the specific MIBC treatment subgroup (*i.e.*, n=43 MIBC patients that received initial treatment with systemic platinum-based chemotherapy).

**Supplementary Table S9.** Overview of previously reported associations and the current replication results for SNPs validated against progression risk in the overall NMIBC patient group of the NBCS using the original and alternative criterion for progression.

|  |  |  |
| --- | --- | --- |
|  | **Original definition progressiona** | **Alternative definition progressionb** |
| **Gene** | **SNP ID** | **A1c** | **A2** | **Genotype counts** **(A1A1/A1A2/A2A2)** | **Additive model** | **Dominant model** | **Recessive model** | **Genotype counts** **(A1A1/A1A2/A2A2)** | **Additive model** | **Dominant model** | **Recessive model** |
| **Event** | **No event** | **HR (95% CI), p** | **HR (95% CI), p** | **HR (95% CI), p** | **Event** | **No event** | **HR (95% CI), p** | **HR (95% CI), p** | **HR (95% CI), p** |
| *RGS1* | rs1323291 | T | G | 159/35/3 | 867/202/18 | 0.96 (0.69-1.33), 0.792 | 0.97 (0.67-1.40), 0.861 | 0.77 (0.21-2.84), 0.698 | 45/15/1 | 981/223/19 | 1.40 (0.85-2.32), 0.186 | 1.51 (0.84-2.71), 0.164 | 1.34 (0.22-8.12), 0.751 |
| *RGS5* | rs10917690 | A | G | 108/79/10 | 566/439/81 | 0.83 (0.63-1.10), 0.194 | 0.85 (0.61-1.20), 0.365 | 0.49 (0.20-1.20), 0.119 | 32/25/4 | 642/493/87 | 0.98 (0.60-1.58), 0.919 | 0.99 (0.54-1.83), 0.987 | 0.85 (0.22-3.28), 0.814 |
| *RGS4* | rs6678136 | G | A | 55/105/37 | 389/506/192 | 1.18 (0.97-1.43), 0.103 | **1.39 (1.02-1.90), 0.038** | 1.08 (0.75-1.54), 0.677 | 17/36/8 | 427/575/221 | 1.05 (0.73-1.49), 0.805 | 1.38 (0.79-2.41) , 0.262 | 0.70 (0.33-1.47), 0.345 |
| *RGS5* | rs11585883 | T | C | 166/29/2 | 936/150/1 | 1.20 (0.83-1.75), 0.339 | 1.13 (0.76-1.66), 0.548 | **10.0 (2.47-40.6), 1.27x10-3** | 54/6/1 | 1048/173/2 | 0.93 (0.45-1.94), 0.851 | 0.81 (0.37-1.77), 0.599 | **11.79 (1.62-85.65), 0.015** |
| *DGCR8* | rs2073778 | C | T | 156/37/4 | 840/228/19 | 0.92 (0.68-1.25), 0.595 | 0.88 (0.63-1.24), 0.475 | 1.23 (0.46-3.31), 0.684 | 48/11/2 | 948/254/21 | 1.00 (0.59-1.72), 0.986 | 0.92 (0.50-1.69), 0.777 | 2.02 (0.49-8.25), 0.330 |
| *DGCR8* | rs720012 | G | A | 156/37/4 | 840/228/19 | 0.92 (0.68-1.25), 0.595 | 0.88 (0.63-1.24), 0.475 | 1.23 (0.46-3.31), 0.684 | 48/11/2 | 948/254/21 | 1.00 (0.59-1.72), 0.986 | 0.92 (0.50-1.69), 0.777 | 2.02 (0.49-8.25), 0.330 |
| *TLR10* | rs4129009 | T | C | 123/66/8 | 718/332/37 | 1.11 (0.86-1.43), 0.440 | 1.12 (0.83-1.51), 0.461 | 1.18 (0.56-2.52), 0.664 | 36/20/5 | 805/377/41 | 1.39 (0.90-2.14), 0.133 | 1.32 (0.78-2.25), 0.301 | 2.54 (0.95-6.82), 0.063 |
| *NOD2* | rs9302752 | C | T | 106/76/15 | 623/411/53 | 1.18 (0.94-1.48), 0.163 | 1.14 (0.86-1.51), 0.351 | 1.56 (0.92-2.64), 0.098 | 35/19/7 | 694/468/61 | 1.18 (0.79-1.78), 0.417 | 0.99 (0.59-1.64), 0.955 | **2.48 (1.13-5.44), 0.024** |
| *UNG* | rs3890995 | T | C | 138/51/8 | 731/320/36 | 0.95 (0.73-1.23), 0.691 | 0.90 (0.66-1.22), 0.493 | 1.24 (0.61-2.52), 0.556 | 42/15/4 | 827/356/40 | 1.08 (0.69-1.70), 0.744 | 0.95 (0.55-1.64), 0.865 | 2.09 (0.75-5.78), 0.157 |
| *NOS2* | rs2297518 | G | A | 131/63/3 | 700/340/47 | 0.86 (0.66-1.11), 0.248 | 0.90 (0.67-1.22), 0.507 | 0.38 (0.12-1.19), 0.097 | 45/15/1 | 786/388/49 | 0.66 (0.39-1.10), 0.109 | 0.64 (0.36-1.14), 0.128 | 0.42 (0.06-3.02), 0.387 |
| *NOS2* | rs2301368 | A | G | 72/98/27 | 347/543/197 | 1.19 (0.96-1.47), 0.108 | 1.39 (0.91-2.14), 0.132 | 1.20 (0.88-1.63), 0.240 | 20/27/14 | 399/614/210 | 1.15 (0.79-1.68), 0.454 | 1.02 (0.58-1.79), 0.9451 | 1.51 (0.81-2.81), 0.196 |
| *TP53* | rs1042522[Pro]/[C]: 41.3% | C | G | 101/76/20 | 589/423/75 | 1.17 (0.94-1.46), 0.157 | 1.14 (0.85-1.52), 0.390 | 1.54 (0.96-2.48), 0.072 | 26/27/7 | 663/471/88 | **1.46 (1.00-2.14), 0.050** | 1.60 (0.95-2.70), 0.079 | 1.76 (0.79-3.95), 0.169 |
| *HRAS* | rs12628 | A | G | 85/94/17 | 500/454/133 | 0.97 (0.78-1.20), 0.784 | 1.10 (0.81-1.48), 0.540 | 0.66 (0.39-1.13), 0.127 | 25/31/5 | 560/518/145 | 1.03 (0.70-1.52), 0.878 | 1.22 (0.71-2.10), 0.468 | 0.68 (0.26-1.77), 0.425 |
| *MTHFR* | rs1801133 | G | A | 99/77/21 | 489/475/123 | 0.88 (0.71-1.09), 0.253 | 0.82 (0.62-1.08), 0.160 | 0.95 (0.61-1.50), 0.839 | 31/22/8 | 557/530/136 | 0.93 (0.64-1.36), 0.701 | 0.81 (0.49-1.34), 0.413 | 1.20 (0.57-2.52), 0.630 |
| *GNAS* | rs7121 | C | T | 64/92/41 | 307/539/241 | 0.88 (0.70-1.11), 0.288 | 0.79 (0.56-1.12), 0.190 | 0.91 (0.60-1.38), 0.650 | 19/31/11 | 353/600/270 | 0.89 (0.59-1.33), 0.557 | 0.91 (0.48-1.72), 0.766 | 0.75 (0.34-1.64), 0.465 |
| *GNB3* | rs5443 | C | T | 86/90/21 | 514/465/107 | 1.08 (0.87-1.33), 0.489 | 1.13 (0.84-1.50), 0.420 | 1.04 (0.65-1.67), 0.854 | 28/28/5 | 573/527/123 | 0.98 (0.66-1.44), 0.903 | 1.04 (0.62-1.74), 0.874 | 0.77 (0.30-2.00), 0.594 |
| *CDKN2A* | rs3088440 | G | A | 159/37/1 | 917/158/12 | 1.21 (0.87-1.68), 0.260 | 1.28 (0.89-1.83), 0.182 | 0.71 (0.12-3.99), 0.694 | 50/10/1 | 1026/185/12 | 1.19 (0.66-2.16), 0.560 | 1.18 (0.61-2.28), 0.629 | 1.81 (0.24-13.69), 0.563 |

**Abbreviations:** SNP: single-nucleotide polymorphism; HR: hazard ratio; CI: confidence interval; NMIBC: non-muscle-invasive bladder cancer; MIBC: muscle-invasive bladder cancer; NBCS: Nijmegen Bladder Cancer Study; DOM: dominant; ADD: additive; REC: recessive.

**a** progression defined as G1/2/2A/low-grade to G2B/3/high-grade; Ta/CIS to T1; T1 to ≥T2; NX/0 to ≥N1; MX/0 to M1

**b** progression defined as Ta/CIS/T1 to ≥T2

**c** A1: major/reference allele; A2: minor/predictive allele (both according to + strand orientation),

**Supplementary references**

[1] Andrew AS, Gui J, Hu T, Wyszynski A, Marsit CJ, Kelsey KT, Schned AR, Tanyos SA, Pendleton EM, Ekstrom RM, Li Z, Zens MS, Borsuk M, Moore JH, Karagas MR. Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study. BJU Int. 2014.

[2] Zhang K, Zhou B, Zhang P, Zhang Z, Chen P, Pu Y, Song Y, Zhang L. Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group. Tumour Biol. 2014;35(5):4031-40.

[3] Lee EK, Ye Y, Kamat AM, Wu X. Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer. 2013;119(9):1643-51.

[4] Ke HL, Chen M, Ye Y, Hildebrandt MA, Wu WJ, Wei H, Huang M, Chang DW, Dinney CP, Wu X. Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. Carcinogenesis. 2013;34(5):1006-11.

[5] Yang X, Li P, Yang X, Qin C, Cao Q, Zhang Z, Wang M, Cai H, Gu J, Tao J, Gu M, Lu Q, Yin C. TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population. Int J Genomics. 2013;2013:473242.

[6] Wang M, Chu H, Li P, Yuan L, Fu G, Ma L, Shi D, Zhong D, Tong N, Qin C, Yin C, Zhang Z. Genetic variants in miRNAs predict bladder cancer risk and recurrence. Cancer Res. 2012;72(23):6173-82.

[7] Wei H, Kamat A, Chen M, Ke HL, Chang DW, Yin J, Grossman HB, Dinney CP, Wu X. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guerin. PLoS One. 2012;7(6):e38533.

[8] Wang M, Wang M, Yuan L, Wu D, Zhang Z, Yin C, Fu G, Wei Q, Zhang Z. A novel XPF -357A>C polymorphism predicts risk and recurrence of bladder cancer. Oncogene. 2010;29(13):1920-8.

[9] Horikawa Y, Nadaoka J, Saito M, Kumazawa T, Inoue T, Yuasa T, Tsuchiya N, Nishiyama H, Ogawa O, Habuchi T. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep. 2008;20(1):49-55.

[10] Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer. Cancer Genet Cytogenet. 2008;184(1):1-8.

[11] Mittal RD, Singh R, Manchanda PK, Ahirwar D, Gangwar R, Kesarwani P, Mandhani A. XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biol Ther. 2008;7(5):645-50.

[12] Sanyal S, De Verdier PJ, Steineck G, Larsson P, Onelov E, Hemminki K, Kumar R. Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms. Acta Oncol. 2007;46(1):31-41.

[13] Lin J, Dinney CP, Grossman HB, Jhamb M, Zhu Y, Spitz MR, Wu X. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet. 2006;70(3):240-5.

[14] Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, Grossman HB, Wu X. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res. 2005;11(4):1408-15.

[15] Zhao H, Liang D, Grossman HB, Wu X. Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology. 2005;66(4):769-74.

[16] Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun Wee J, Kim WJ. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology. 2005;65(1):70-5.

[17] Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila). 2010;3(10):1235-45.

[18] Gangwar R, Ahirwar D, Mandhani A, Mittal RD. Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population? Mutat Res. 2009;680(1-2):56-63.

[19] Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005;23(24):5746-56.

[20] Lima L, Oliveira D, Ferreira JA, Tavares A, Cruz R, Medeiros R, Santos L. The role of functional polymorphisms in immune response genes as biomarkers of BCG Immunotherapy outcome in bladder cancer: Establishment of a predictive profile in a Southern Europe population. BJU Int. 2014.

[21] Lima L, Ferreira JA, Tavares A, Oliveira D, Morais A, Videira PA, Medeiros R, Santos L. FASL polymorphism is associated with response to bacillus Calmette-Guerin immunotherapy in bladder cancer. Urol Oncol. 2014;32(1):44 e1-7.

[22] Jaiswal PK, Singh V, Srivastava P, Mittal RD. Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. Gene. 2013;519(1):128-34.

[23] Srivastava P, Kapoor R, Mittal RD. Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol Oncol. 2013;31(2):247-54.

[24] Jaiswal PK, Goel A, Mandhani A, Mittal RD. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep. 2012;39(5):5615-21.

[25] Chiong E, Kesavan A, Mahendran R, Chan YH, Sng JH, Lim YK, Kamaraj R, Tan TM, Esuvaranathan K. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol. 2011;59(3):430-7.

[26] Mittal RD, Srivastava P, Mittal T, Verma A, Jaiswal PK, Singh V, Mandal RK, Mandhani A. Association of death receptor 4, Caspase 3 and 5 gene polymorphism with increased risk to bladder cancer in North Indians. Eur J Surg Oncol. 2011;37(8):727-33.

[27] Gangwar R, Mandhani A, Mittal RD. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery. 2011;149(1):126-34.

[28] Srivastava P, Jaiswal PK, Singh V, Mittal RD. Role of p53 gene polymorphism and bladder cancer predisposition in northern India. Cancer Biomark. 2010;8(1):21-8.

[29] Gangwar R, Mittal RD. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol. 2010;29(7):349-56.

[30] Gangawar R, Ahirwar D, Mandhani A, Mittal RD. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India. Med Oncol. 2010;27(2):159-66.

[31] Gangwar R, Mandhani A, Mittal RD. XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. J Cancer Res Clin Oncol. 2010;136(5):779-86.

[32] Ahirwar DK, Mandhani A, Mittal RD. IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort. Arch Med Res. 2010;41(2):97-103.

[33] Vazquez-Lavista LG, Lima G, Gabilondo F, Llorente L. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology. 2009;74(2):414-8.

[34] Ahirwar DK, Mandhani A, Dharaskar A, Kesarwani P, Mittal RD. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy. BJU Int. 2009;104(6):867-73.

[35] Gangwar R, Mandhani A, Mittal RD. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population. Ann Surg Oncol. 2009;16(7):2028-34.

[36] Ahirwar DK, Agrahari A, Mandhani A, Mittal RD. Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers. 2009;14(4):213-8.

[37] Decobert M, Larue H, Bergeron A, Harel F, Pfister C, Rousseau F, Lacombe L, Fradet Y. Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2006;175(4):1506-11.

[38] Basturk B, Yavascaoglu I, Oral B, Goral G, Oktay B. Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy. Cytokine. 2006;35(1-2):1-5.

[39] Guirado M, Gil H, Saenz-Lopez P, Reinboth J, Garrido F, Cozar JM, Ruiz-Cabello F, Carretero R. Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer. Hum Immunol. 2012;73(6):668-72.

[40] Ryk C, Wiklund NP, Nyberg T, De Verdier PJ. Ser608Leu polymorphisms in the nitric oxide synthase-2 gene may influence urinary bladder cancer pathogenesis. Scand J Urol Nephrol. 2011;45(5):319-25.

[41] Ryk C, Steineck G, Wiklund NP, Nyberg T, de Verdier PJ. The (CCTTT)n microsatellite polymorphism in the nitric oxide synthase 2 gene may influence bladder cancer pathogenesis. J Urol. 2010;184(5):2150-7.

[42] Sanyal S, Ryk C, De Verdier PJ, Steineck G, Larsson P, Onelov E, Hemminki K, Kumar R. Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms. Scand J Urol Nephrol. 2007;41(3):182-90.

[43] Frey UH, Eisenhardt A, Lummen G, Rubben H, Jockel KH, Schmid KW, Siffert W. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(4):871-7.

[44] Eisenhardt A, Siffert W, Rosskopf D, Musch M, Mosters M, Roggenbuck U, Jockel KH, Rubben H, Lummen G. Association study of the G-protein beta3 subunit C825T polymorphism with disease progression in patients with bladder cancer. World J Urol. 2005;23(4):279-86.

[45] Sakano S, Berggren P, Kumar R, Steineck G, Adolfsson J, Onelov E, Hemminki K, Larsson P. Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene. Int J Cancer. 2003;104(1):98-103.

[46] Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, Critelli R, Russo A, Andrew AS, Ye Y, Wu X, Kiemeney LA, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Vineis P, Matullo G. Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy. Int J Cancer. 2013;133(8):2004-9.

[47] Djukic TI, Savic-Radojevic AR, Pekmezovic TD, Matic MG, Pljesa-Ercegovac MS, Coric VM, Radic TM, Suvakov SR, Krivic BN, Dragicevic DP, Simic TP. Glutathione S-transferase T1, O1 and O2 polymorphisms are associated with survival in muscle invasive bladder cancer patients. PLoS One. 2013;8(9):e74724.

[48] Kim EJ, Yan C, Ha YS, Jeong P, Yi Kim I, Moon SK, Choi YH, Kim WJ. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: a novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urol Oncol. 2012;30(5):673-9.

[49] Ha YS, Yan C, Kim IY, Yun SJ, Moon SK, Kim WJ. Tissue hOGG1 genotype predicts bladder cancer prognosis: a novel approach using a peptide nucleic acid clamping method. Ann Surg Oncol. 2011;18(6):1775-81.

[50] Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis. 2010;31(8):1387-91.

[51] Mason RA, Morlock EV, Karagas MR, Kelsey KT, Marsit CJ, Schned AR, Andrew AS. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis. 2009;30(7):1155-60.

[52] Castillejo A, Rothman N, Murta-Nascimento C, Malats N, Garcia-Closas M, Gomez-Martinez A, Lloreta J, Tardon A, Serra C, Garcia-Closas R, Chanock S, Silverman DT, Dosemeci M, Kogevinas M, Carrato A, Soto JL, Real FX. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer. 2009;124(3):608-13.

[53] Andrew AS, Gui J, Sanderson AC, Mason RA, Morlock EV, Schned AR, Kelsey KT, Marsit CJ, Moore JH, Karagas MR. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet. 2009;125(5-6):527-39.

[54] Teo MT, Dyrskjot L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Orntoft TF, Bishop DT, Kiltie AE. Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. Ann Oncol. 2014;25(4):877-83.

[55] Teo MT, Landi D, Taylor CF, Elliott F, Vaslin L, Cox DG, Hall J, Landi S, Bishop DT, Kiltie AE. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis. 2012;33(3):581-6.

[56] Shinohara A, Sakano S, Hinoda Y, Nishijima J, Kawai Y, Misumi T, Nagao K, Hara T, Matsuyama H. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci. 2009;100(12):2376-82.

[57] Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, Ito H, Ohmi C, Matsuyama H, Naito K. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer. 2006;95(5):561-70.

[58] Gallagher DJ, Vijai J, Hamilton RJ, Ostrovnaya I, Iyer G, Garcia-Grossman IR, Kim PH, Przybylo JA, Alanee S, Riches JC, Regazzi AM, Milowsky MI, Offit K, Bajorin DF. Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. Ann Oncol. 2013;24(9):2414-21.

[59] Nikitas N, Karadimou A, Tsitoura E, Soupos N, Tsiatas M, Karavasilis V, Pectasides D, Pavlidis N, Chrisofos M, Adamakis I, Murray S, Fountzilas G, Dimopoulos MA, Bamias A. Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study. Pharmacogenomics. 2012;13(14):1595-607.